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Résumé 
Les effets cardiovasculaires des alpha-2 agonistes, particulièrement importants chez les 
chiens, limitent leur utilisation en pratique vétérinaire. La perfusion à débit constant (PDC) 
de ces drogues, comme la médétomidine (MED) permettrait un contrôle plus précis de ces 
effets. Les effets hémodynamiques de plusieurs doses de MED en PDC ont été évalués chez 
le chien. 
Lors de cette étude prospective, réalisée en double aveugle, 24 chiens en santé, ont 
reçu de façon aléatoire une des 6 doses de MED PDC (4 chiens par groupe). Les chiens ont 
été ventilés mécaniquement pendant une anesthésie minimale standardisée avec de 
l’isoflurane dans de l’oxygène. Une dose de charge (DC) de médétomidine a été 
administrée aux doses de 0.2, 0.5, 1.0, 1.7, 4.0 ou 12.0 µg/kg pendant 10 minutes, après 
laquelle la MED PDC a été injectée à une dose identique à celle de la DC pendant 60 
minutes. L’isoflurane a été administré seul pendant une heure après l’administration d’une 
combinaison d’ISO et de MED PDC pendant 70 minutes. La fréquence cardiaque (FC), la 
pression artérielle moyenne (PAM) et l’index du débit cardiaque (IC) ont été mesurés. Des 
prélèvements sanguins ont permis d’évaluer le profil pharmacocinétique. D’après ces 
études, les effets hémodynamiques de la MED PDC pendant une anesthésie à l’isoflurane 
ont été doses-dépendants. L’IC a diminué progressivement alors que la dose de MED 
augmentait avec: 14.9 (12.7), 21.7 (17.9), 27.1 (13.2), 44.2 (9.7), 47.9 (8.1), and 61.2 (14.1) 
% respectivement. Les quatre doses les plus basses n’ont provoqué que des changements 
minimes et transitoires de la FC, de la PAM et de l’IC. La pharmacocinétique apparaît 
clairement dose-dépendante. De nouvelles expériences seront nécessaires afin d’étudier 
l’utilisation clinique de la MED PDC. 
 
Mots-clés: Médétomidine, Perfusion à Débit Constant (PDC), Sédation, Analgésie, 
Anesthésie, Chien 
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Abstract 
The cardiovascular effects of alpha-2 agonists, particularly pronounced in dogs, limit their 
use in veterinary practice. The use of these drugs, namely medetomidine (MED), by 
constant rate infusion (CRI), could allow more precise control of the cardiovascular effects. 
The haemodynamic responses of MED CRI at several dosages in dogs were investigated. 
In a prospective, blinded study, 24 healthy beagles randomly received one of 6 
MED CRI regimens (4 dogs per regimen). Dogs were mechanically ventilated to maintain 
stable low-level isoflurane (ISO) anaesthesia in oxygen. A loading MED infusion was 
administered at 0.2, 0.5, 1.0, 1.7, 4.0 or 12.0 µg·kg-1 for 10 min, followed by maintenance 
CRI for 60 min providing identical dose amounts for all dogs (total duration for MED and 
ISO: 70 min). Isoflurane was then administered alone for an additional hour. Heart rate 
(HR), mean arterial blood pressure (MAP), and cardiac index (CI) were recorded. Blood 
sampling was performed to establish pharmacokinetic profiles.  
Based on this study, the hemodynamic effects of MED CRI during ISO anaesthesia 
were found to be dose-dependent. Baseline CI decreased dose-dependently as MED dose 
increased by: 14.9 (12.7), 21.7 (17.9), 27.1 (13.2), 44.2 (9.7), 47.9 (8.1), and 61.2 (14.1) % 
respectively. The four lowest dosages created limited and transient changes in HR, MAP, 
and CI. Pharmacokinetics were dose-dependent. Further investigations for perioperative use 
are warranted. 
 
Keywords: Medetomidine, Constant rate infusion (CRI), Sedation, Analgesia, Anaesthesia, 
Dog 
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 Introduction 
 
In recent years, pain management in veterinary medicine has become increasingly 
important. Pain assessment and alleviation is now a discipline, and is particularly developed 
in small animal practice. It brings together an increasing number of veterinarians and 
technicians devoted to the promotion, enhancement, and advancement of pain management 
in animals. 
Analgesic agents that are widely used in clinical practice, include opioids and non-
steroidal analgesic drugs (NSAIDs). In North-America opioids are the major players for 
systemic analgesia in veterinary medicine with butorphanol being one of the most popular 
analgesic drugs currently used in Canadian small animal practices. However, potential risks 
exist for adverse and at times deleterious effects in patients with opioid administration 
which may include constipation, urinary retention, respiratory depression, bradycardia, 
dysphoria, and opioid-induced hyperalgesia. 
Alpha-2 agonists, namely medetomidine (the most commonly used alpha-2 agonist 
in small animal practice in Canada; Kaartinen et al., 2007), could provide an alternative or 
additive effect to opioid protocols used in peri-operative analgesia. Medetomidine is a 
potent analgesic, sedative, muscular relaxant, and is anxiolytic as well as reversible. It is 
primarily used for sedation and pre-medication prior to general anaesthesia. However, in 
spite of its claimed analgesic potency, it has not been used to its full extent as a peri-
operative analgesic adjunct. Concerns about the cardiovascular side effects of alpha-2 
agonists after one bolus injection, especially in dogs, have somewhat prevented full 
adoption of these agents in veterinary practice. 
The use of medetomidine through constant rate infusion (CRI) in dogs is a relatively 
new approach, although not thoroughly explored. With the use of CRI, the cardiovascular 
side effects may be minimized and plasma concentrations are more stable than with 
frequent bolus injections. 
 The objective of this study was to investigate an alternative or supplemental 
analgesic drug protocol to opioids, by intravenous delivery of medetomidine at CRI in 
dogs. The hypothesis of this study was to identify a dosage level of medetomidine CRI 
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causing minimal hemodynamic changes usually associated to alpha-2 agonists whilst 
allowing precise control of both sedation and analgesia duration.  
 FIRST CHAPTER – LITERATURE REVIEW 
1.0 PHYSIOLOGY AND PHARMACOLOGY OF THE ALPHA-2 AGONISTS 
 
 
1.1 Agonists 
Alpha-2 agonists act on alpha-2-adrenoceptors by inhibiting the sympathetic tone (decreased 
release and turnover of noradrenaline) and increasing the parasympathetic tone (Cullen, 
1999). This leads to characteristic hemodynamic effects (e.g. decreased heart rate and 
cardiac output) as well as a range of anxiolytic, sedative, and analgesic effects. 
The alpha-2 agonists available for clinical use in veterinary medicine are xylazine, 
medetomidine, detomidine, and romifidine. Medetomidine is mostly used in small animal 
practice and is licensed for use in dogs, in Canada. Medetomidine is a highly selective 
alpha-2 agonist. The chemical structure is shown in figure 1. It is supplied in a racemic 
mixture of two optical enantiomers (dexmedetomidine and levomedetomidine). 
Dexmedetomidine is the active enantiomer (Virtanen, 1989; Murrell and Hellebrekers, 
2005; Kuusela et al., 2000). The pure form of dexmedetomidine has recently been launched 
for the veterinary market but was unavailable in Canada in 2009. Dexmedetomidine is the 
most potent alpha-2 agonist available for clinical use in veterinary medicine. It has a very 
high affinity for alpha-2 adrenoceptors where it acts as a full agonist. It has a selectivity 
ratio of 1620/1 (α2/α1) which is 5 to 10 times higher than that of xylazine (α2/α1 ratio 
160/1) and detomidine (260/1) (Virtanen, 1989; Cullen, 1996). Thus, medetomidine and 
dexmedetomidine have a very low affinity to alpha-1 adrenoceptors, compared to other 
alpha-2 agonists, such as xylazine and clonidine. Medetomidine seems to provide better 
sedation and analgesia than xylazine, possibly due to its higher selectivity (Tyner et al., 
1997). 
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Figure 1. Chemical structure of medetomidine. (From Orion Pharmos Inc. info brochure of 
medetomidine.) 
 Medetomidine, dexmedetomidine and detomidine are the only clinically available 
alpha-2 agonists in veterinary practice that have an imidazole ring in their structure enabling 
these compounds to also interact with the imidazoline receptor (Murrell and Hellebrekers, 
2005). Xylazine and romifidine do not possess this property. Studies with 
dexmedetomidine have shown that one of its cardiovascular properties was also mediated 
via these receptors. Interestingly it was demonstrated to have a cardioprotective effect; an 
antiarrhythmic effect via imidazoline receptors in the CNS as well as enhancing vagal tone 
(Kamibayashi et al., 2000; Kamibayashi et al., 1995A & B). 
Medetomidine can be given intramuscularly (IM), intravenously (IV) or 
subcutaneously (SC). After IM administration, the drug is rapidly absorbed and peak 
plasma levels are reached within 30 minutes. When given IV, the onset of action is rapid 
but the peripheral effects on the cardiovascular system are more pronounced than when 
given IM. After SC administration in dogs, the absorption time of the drug is slow and 
extremely variable which makes this route of administration less favourable (England and 
Clarke, 1989). 
In North-America, the recommended dosage range of medetomidine in healthy dogs 
is 10-40 µg/kg (Paddleford and Harvey, 1999). Earlier studies searching for optimal dosage 
of medetomidine in clinical practice suggested 30-40 µg/kg for dogs (Vähä-Vahe, 1989A), 
750 µg/m2 IV and 1000 µg/m2 IM (Hamlin and Bernarski, 1989). Although clinically 
difficult, it has been suggested by the manufacturer that dosages calculated as µg per body 
surface area would be more accurate than those calculated per body weight. 
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In a clinical study, the optimal dosage recommended for medetomidine was 15-20 
µg/kg for radiological examinations and a dosage of 30-40 µg/kg was necessary for 
sufficient restraint and analgesia for clinical examinations or minor interventions (Nilsfors 
et al., 1989). The highest dosage of medetomidine recommended for dogs was 80 µg/kg 
(Vainio, 1989A). 
However, much lower doses may be adequate for perioperative use when given with 
other anaesthetic and analgesic drugs, since the sedative and analgesic effects of 
medetomidine are very potent (Bergström, 1988). Low dose bolus administration and low 
dose infusion are now preferred in clinical practice. 
 
1.2 Receptors 
Alpha-2-adrenoceptors are widely distributed throughout tissues and organs where they 
mediate the effects of endogenous catecholamines. Receptors are located both 
presynaptically and postsynaptically. Postsynaptic alpha-2-adrenoceptors in peripheral 
blood vessels mediate vasoconstriction leading to increased blood pressure. Presynaptic 
alpha-2-adrenoceptors regulate the release of noradrenaline, the sympathetic 
neurotransmitter from adrenergic nerve endings. These receptors control the concentration 
of catecholamines in the extracellular space of nerve endings. If these receptors are 
occupied by a synthetic alpha-2 agonist (ex. medetomidine) the nerve impulses through the 
synapse are decreased resulting in sympatholysis (decrease in central noradrenergic tone). 
Sedation and analgesia occur along with a centrally mediated decrease in heart rate and 
attenuation of vasoconstriction leading to reduced blood pressure. The overall 
hemodynamic response to systemically administered alpha-2 agonists may be determined by 
receptors within the central nervous system (CNS) and spinal cord (Aantaa and Jalonen, 
2006). However, it was also suggested that this response in dogs depends on the initial 
status of vessel tone (Lin et al., 2008). 
Other physiological functions have been found for alpha-2-adrenoceptors located 
postsynaptically, for example, in renal, hepatic, pancreatic, adipose and ocular tissues, and 
in thrombocytes, as well as vascular smooth muscle (Murrell and Hellebrekers, 2005). 
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Adrenoceptors are classified in three main classes (β-, α1-, and α2-adrenoceptors). 
In general, the sedative and anxiolytic effects of alpha-2 agonists are mediated by activation 
of supraspinal autoreceptors (receptors located on noradrenergic neurons) located in the 
pons (locus ceruleus; LC; Figure 2). Analgesic effects are mediated by activation of spinal 
heteroceptors (receptors located on non-noradrenergic neurons) located in the dorsal horn 
of the spinal cord (Lemke, 2004A). However, the supraspinal autoreceptors located in the 
pons also play a prominent role in descending modulation of nociceptive input (Lemke, 
2004B; Cullen, 1996; Ossipov et al., 1990). 
Three distinct alpha-2 receptor subtypes (A, B and C) have been identified (Maze 
and Fujinaga, 2000). Alpha-2A receptors mediate sedation, analgesia, hypotension, and 
bradycardia. Alpha-2B receptors mediate the initial increase in vascular resistance, 
hypertensive action, and reflex bradycardia. Alpha-2C receptors mediate the hypothermia 
that may accompany administration of alpha-2 agonists. Centrally located alpha-2C receptors 
also mediate anxiolysis. Drugs acting via these receptors may have therapeutic value in 
decreasing the stress response, for example in the case of post-traumatic stress disorders 
(Kamibayashi et al., 2000). 
Alpha-2 receptors are cell membrane proteins that trigger cellular responses to 
ligands by interacting with intracellular G-proteins (Aantaa et al., 1995). These receptors 
are capable of interacting with all types of pertussis toxin-sensitive G-proteins, although the 
most important interactions are with the inhibitory G-proteins Gi and Go. Intracellular 
second-messenger pathways include inhibition of adenylate cyclase and modulation of ion 
channels. 
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Figure 2. Descending antinociceptive pathways. Noradrenergic neurons project from 
supraspinal levels to the neurons in the dorsal horn of the spinal cord. (From Kandel 
Schwartz and Jessel, Principles of Neural Science, 4th edition, 2000, McGraw-Hill.)   
                          
1.3 Pharmacokinetics 
Pharmacokinetic studies have shown that absorption occurs rapidly following 
medetomidine (IM) administration in dogs. Plasma protein binding of medetomidine is 
very high (92-95%) (Salonen, 1989). Thus, medetomidine is present in the circulation 
mostly in its inactive protein-bound form. Medetomidine, a weak organic base, when given 
  
8
 
at high dosage (80 µg/kg) presented a low free fraction (fu) estimated at 15% in dogs, cats, 
and rats. Binding of the drug to α-proteins (globulins, lipoproteins, glycoproteins) was 
hypothesized. Due to high lipid solubility, there is rapid distribution, systemic diffusion, 
and clearance. In a pharmacokinetic study with radioactively labelled 3H-medetomidine, 
serum peak concentration (approximately 20 ng/ml) was obtained 30 minutes after 
administration at a dosage of 80 µg/kg (Salonen, 1989). The volumes of distribution at 
steady state (Vss), the clearances (Cl), and half-lives of elimination (T½) after IV and IM 
administration of this dosage are shown in Table I. Similar pharmacokinetic data were 
shown in a study by Kuusela et al. (2000), in which they compared pharmacokinetics of 
medetomidine, levomedetomidine, and dexmedetomidine after IV bolus administration. 
The data are included in Table I. 
 
 Vss (l/kg) Cl (l/h/kg) T½ (h) 
Medetomidine IM 80 µg/kg 
Medetomidine IV 80 µg/kg 
(Salonen, 1989) 
 3.0 
 2.8 
1.65 (27.5 ml/min/kg) 
2.00 (33.4 ml/min/kg) 
1.28 
0.97 
Medetomidine IV 40 µg/kg  1.28 1.26 0.96 
Dexmedetomidine IV 20 µg/kg  0.86 1.24 0.78 
Levomedetomidine IV 20 µg/kg 
(Kuusela et al., 2000) 
 2.68 4.07 0.63 
Table I. Pharmacokinetic parameters of medetomidine, dexmedetomidine, and 
levomedetomidine (information obtained from Salonen, 1989; and Kuusela et al., 2000). 
Vss = volume of distribution at steady state, Cl = clearance, T½ = elimination half-life. 
 
The clearance of levomedetomidine appears more rapid than dexmedetomidine or 
racemic medetomidine in dogs (Table I; Kuusela et al., 2000). In addition, 
levomedetomidine has been shown to interfere with the metabolism of other anesthetic 
drugs in the liver, such as slowing ketamine metabolism (Kharasch et al., 1992). 
In healthy human adults, dexmedetomidine pharmacokinetic profile includes a rapid 
distribution phase, T½ of 2 h, and Vss of 118 L (Dyck and Shafer, 1993). Based on 
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available pharmacokinetic data, the T½ after bolus administration suggests more rapid 
elimination in dogs compared to humans, while the Vss with 40 µg/kg (IV) in dogs is 
similar to weight-adjusted results in humans. 
Dexmedetomidine and medetomidine undergoes hepatic metabolism with limited 
unchanged drug excreted in the urine or feces. Medetomidine is mainly (80-90%) 
metabolized by hepatic hydroxylation followed by glucuronidation in dogs, involving 
several biotransformation pathways (Salonen, 1992). Phase I reaction proceeds with a rate 
sufficient for rapid removal of the drug from the animal’s body and is therefore regulated 
mainly by hepatic blood flow. Phase II glucuronidation of medetomidine with glucuronic 
acid is accomplished by different UDP-glucuronosyltransferases presenting different 
affinity, regio-and stereo-selectivity in human and canine liver microsomes. N-
glucuronidation of levomedetomidine and dexmedetomidine thus occur with different 
kinetics (Kaivosaari et al., 2008). In addition, an O-glucuronidation pathway has been 
reported for medetomidine (Salonen, 1992). 
A phenotypic polymorphism of the cytochrome P450 (CYP)-catalyzed phase I 
hydroxylation of medetomidine, affecting the biotransformation rate of medetomidine has 
been reported in rabbits (Avsaroglu et al., 2008) However, this has not been demonstrated 
in dogs. In a report from Dutta et al. (2000), there is pharmacodynamic alteration of 
medetomidine clearance in humans with increasing dosage as a result of medetomidine-
induced cardiac output decrease, and reduced hepatic blood flow decreasing hepatic 
clearance. However, it is likely that major species differences in medetomidine metabolism 
may exist (Kaivosaari et al., 2002). 
 In human adults with severe hepatic failure, Vss and T½ were increased and 
clearance decreased (Cunningham et al., 1999). In adults with severe renal disease, there 
was no significant difference between renal disease and control patients for Vss and 
clearance. However, the T½ was decreased with renal disease, while the perceived clinical 
sedation was prolonged. 
  In children, the pharmacokinetic profile appears similar to adults except in very 
young infants. The neonates have been reported to clear dexmedetomidine faster (Tobias, 
2007). By contrast, in another study using population analysis techniques, clearance in 
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neonates was approximately one-third of that described in adults (Potts et al., 2008). In 
addition, two studies in paediatric patients showed either comparable pharmacokinetic data 
to adults (Diaz et al., 2007), or slightly different data with respect to larger weight-adjusted 
Vss in children younger than 2 years of age (Vilo et al., 2008), indicating a need for larger 
loading doses in younger infants. 
 
 
2.0 CARDIOVASCULAR EFFECTS  
 
Alpha-2-adrenoceptor agonists have severe physiological cardiovascular side effects. They 
can produce a biphasic blood pressure response, a decrease in heart rate and cardiac index, 
and an increase in systemic vascular resistance index and central venous pressure. 
Myocardial contractility and perfusion are decreased and dysrhythmias can be present 
(Savola, 1989; Vainio, 1989A). Minimal changes in pulmonary arterial pressure or 
pulmonary capillary wedge pressure have been reported (Kuusela et al., 2000; Pypendop 
and Verstegen, 1998; Bloor et al., 1992). 
Alpha-2 agonists induce dose-dependent changes in cardiovascular function (Vainio 
and Palmu, 1989B). The effects of medetomidine on heart rate have been found to be, to a 
certain extent, dose dependent in dogs (Bergström, 1988; Pypendop and Verstegen, 1998). 
However, in a dose titration study, only the lowest dosages (1-2 µg/kg IV) induced less 
pronounced effects compared to higher doses. Even at a dosage as low as 5 µg/kg IV nearly 
maximal cardiovascular effects were observed. Dosages above this value minimally further 
influenced cardiovascular function, while the duration of these effects was prolonged 
(Pypendop and Verstegen, 1998). 
Even though cardiovascular effects of medetomidine and dexmedetomidine are 
mainly seen as adverse effects to the patient, studies in animal models (Roekaerts et al., 
1996; Okada et al., 2007) and studies on human patients support evidence of 
cardioprotective effect especially in patients who either have, or are at high risk of 
developing, cardiac disease (Aantaa and Jalonen, 2006). A meta-analysis of human trials 
demonstrated reduced mortality and myocardial infarction with the use of alpha-2 agonists 
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in patients undergoing non-cardiac, vascular surgery (Wijeysundera et al., 2003). In 
addition, dexmedetomidine was associated with a trend toward improved cardiac outcomes 
during non-cardiac surgery which was shown by a decrease both in mortality and non-fatal 
myocardial infarction or myocardial ischemia (Biccard et al., 2008). In a canine 
experiment, dexmedetomidine had cardioprotective effects by optimizing coronary artery 
blood flow (Roekaerts et al., 1996). In an isolated rat heart model, dexmedetomidine had a 
cardioprotective effect on global ischemia, which was mediated by alpha-2 adrenergic 
receptors (Okada et al., 2007). Since peri-operative hemodynamic responses are identified 
as major indicators of increased risk for post-operative cardiac complications in human 
patients, the hemodynamic stability induced by low-dose alpha-2 agonist administration 
may reduce the risk of cardiac events (Aantaa and Jalonen, 2006). 
 
2.1 Blood pressure 
 
There is an initial transient rise in blood pressure (hypertensive phase) during the first few 
minutes following IV injection (due to peripheral vasoconstriction through stimulation of 
postsynaptic alpha-2-adrenoceptors of vascular smooth muscle), followed by a 
baroreceptor-mediated decrease in heart rate leading to sinus bradycardia. After a transient 
rise, arterial blood pressure falls to normal or below normal levels (hypotensive phase) 
(Short, 1992; Hall and Clarke, 1991) as the central effects of alpha-2 agonists appear to 
predominate (due to stimulation of presynaptic receptors located in the CNS).  
 In human patients, the hypotensive phase seems to predominate even during a 
loading dose administration. However, hypertension may be seen on rare occasions 
(Tobias, 2007). The actions on blood pressure in humans are dose- and dose regimen-
dependant: systemic blood pressure increases when therapeutic concentrations are 
significantly exceeded, and transient hypertension may occur during rapid administration of 
a loading dose. With appropriate doses, alpha-2 agonists reliably control heart rate and 
blood pressure, thus augmenting hemodynamic stability in human patients undergoing 
surgery (Aantaa and Jalonen, 2006). 
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2.2 Heart rate 
 
Heart rate was shown to decrease significantly after alpha-2 agonist administration. In a 
study in laboratory beagles, medetomidine given at 40 µg/kg IM decreased heart rate by 
63% (Vainio, 1991). In another study, heart rate decreased by 63% at all dosages (40, 80, 
and 160 µg/kg) with both IM and IV administration, 2-4 minutes after injection in dogs 
(Vainio, 1989A). Decreased heart rate may be a form of sinus bradycardia. First and second 
degree atrioventricular (AV) blocks may also be observed (Short, 1992). Heart rate may 
decrease dramatically with higher doses; decreases can reach 75% of control values (Short, 
1992). Heart rates with values of 35 bpm may be seen with elevated doses. The decrease in 
heart rate is partly a physiological vagally mediated baroreceptor reflex to the initial 
hypertension and increased afterload (Maze and Tranquilli, 1991), and partly a centrally-
mediated decrease due to decreased sympathetic tone. However, lower dosages (0.5-5 
µg/kg) of medetomidine are presently used in clinical practice because they are associated 
with milder effects on heart rate. Increasing interest exists to exploit the centrally-mediated 
sympatholytic properties of alpha-2 agonists, since it may effectively blunt the potentially 
deleterious increases in heart rate and blood pressure (Aantaa and Jalonen, 2006), and thus 
increase hemodynamic stability. This may be especially important during emergence from 
anaesthesia, when heart rate often accelerates in response to increased sympathetic drive. 
 
2.2.1 Decreased heart rate and oxygen consumption 
 
Following medetomidine administration, bradycardia is accompanied by a proportional 
reduction in myocardial oxygen consumption, ensuring oxygen requirements of the heart 
(Short, 1992; Murrell and Hellebrekers, 2005). Dexmedetomidine was found to decrease 
myocardial energy requirements and oxygen consumption, in parallel with decreased 
myocardial blood flow and oxygen supply (Lawrence et al., 1996B). Lowering heart rate 
and thereby oxygen consumption provide beneficial effects in human patients with 
coronary artery disease by preventing deleterious tachycardia in response to stressful 
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situations (Tobias, 2007; Aantaa and Jalonen, 2006). These benefits of dexmedetomidine in 
cardiac patients provide cardioprotection by reducing risks of myocardial ischaemia 
(Aantaa and Jalonen, 2006). 
 
2.3 Cardiac output 
 
Cardiac output decreases and peripheral resistance increases following alpha-2 agonist 
administration in dogs (Short, 1992). A precise mechanism accounting for the huge 
reduction in cardiac output remains unknown although several mechanisms have been 
suggested. These mechanisms include a direct myocardial depressant effect, drug-induced 
decrease of metabolic demands, and decrease in response to alpha-2 agonist-mediated 
increase in afterload. Other mechanisms also include decrease in heart rate, myocardial 
hypoxia and dysfunction in response to coronary vasoconstriction, and decrease in plasma 
circulating catecholamines (Murrell and Hellebrekers, 2005; Bloor et al., 1992; Housmans, 
1990). It is likely that several of these mechanisms are involved together to decrease 
cardiac output during alpha-2 agonist administration. These mechanisms are briefly 
discussed below. 
A study with medetomidine in autonomically (pharmacologically) blocked dogs 
showed that the cardiac depressor effect of medetomidine is most likely attributable to an 
increase in peripheral vascular resistance caused by postsynaptic activation of alpha-2 
receptors in the peripheral vasculature. In that study, medetomidine did not produce any 
direct myocardial negative inotropic effect (Autran de Morais et al., 1995). To support 
these findings, other studies have been published on dexmedetomidine. One of them 
showed that dexmedetomidine in isolated dog hearts (peripheral alpha-2 receptors were 
ruled out) did not show depressant effects (Flacke et al., 1992). In addition, another study 
concluded that dexmedetomidine did not seem to produce direct negative inotropic or 
chronotropic myocardial effects (Housmans, 1990). 
It has been suggested that cardiac output decreases in response to dexmedetomidine, 
as a result of the increased afterload provoked by increased systemic vascular resistance 
(Bloor et al., 1992). However, increased systemic vascular resistance alone could not 
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account for the degree of cardiac output depression recorded in dogs given 
dexmedetomidine, because the normal canine heart maintains cardiac output when afterload 
is increased even when the heart is denervated (Murrell and Hellebrekers, 2005; Flacke et 
al., 1992).  
Drug-induced decrease in metabolic demands could account for some of the 
reduction in cardiac output. However, it is unlikely that it could account alone for the high 
degree of cardiac output depression. 
Dexmedetomidine does not seem to cause myocardial hypoxia, despite the fact that 
dexmedetomidine induces vasoconstriction in coronary arteries (Coughlan et al., 1992). 
Dexmedetomidine induces coronary blood flow reduction in anaesthetized dogs. This 
reduction was associated to increased coronary vascular resistance and increased oxygen 
extraction from the coronary blood supply (Flacke et al., 1993). However, alpha-2 agonists 
induce a reduction in myocardial oxygen demand in parallel with decreased oxygen supply 
(due to coronary vasoconstriction) in healthy dogs. Thus, the oxygen delivery is maintained 
above the level of oxygen demand of the myocardium. 
The circulating plasma catecholamines are reduced to almost undetectable levels 
after dexmedetomidine administration (20 µg/kg IV). This causes a reduction in inotropic 
support which may thus decrease cardiac output. However, this reduction was shown to 
occur without sympathetic support in spinal sympathectomized dogs (Bloor et al., 1992) 
and therefore does not fully explain the cardiac output reduction due to alpha-2 agonist 
administration in dogs. 
Heart rate decrease seems to be an important factor in the cardiac output reduction 
by medetomidine and dexmedetomidine. Nevertheless, this factor alone does not seem to 
account for the degree of cardiac output depression, since anticholinergic pretreatment 
(glycopyrrolate), used to correct bradycardia, diminished the cardiac output reduction only 
by one-third (Bloor et al., 1992). 
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2.4 Heart rhythm 
 
Earlier studies raised concerns that high levels of alpha-2 agonists sensitized myocardium to 
epinephrine-induced arrhythmias in halothane or isoflurane anaesthetized dogs. Indeed, 
xylazine (1.1 mg/kg IV followed by infusion at 1.1 mg/kg/h) was found to increase the 
likelihood of dysrhythmias in halothane- and isoflurane-anaesthetized dogs (Tranquilli et 
al., 1988; Muir et al., 1975). 
Subsequent studies in dogs showed that lower levels of alpha-2 agonists, 
medetomidine (750 µg/m2 IV or 15 µg/kg IM) or xylazine (1.1 mg/kg IV or IM), did not 
facilitate the development of re-entrant ventricular arrhythmias in isoflurane or halothane 
anaesthetized dogs (Tranquilli et al., 1988; Pettifer, et al., 1996; Dyson and Pettifer, 1997; 
Lemke and Tranquilli, 1994, Lemke et al., 1993A & B). In fact, when anaesthetic-induced 
arrhythmogenicity is a concern, selection of the inhalation agent may be a more important 
consideration than the selection of alpha-2 agonists. 
Furthermore, decreased sympathetic tone and increased parasympathetic tone 
induced by lower doses of alpha-2 agonist dexmedetomidine (0.1, 0.2, and 0.5 µg/kg/min) 
appear to attenuate the development of epinephrine-induced arrhythmias in dogs. This 
action seems to be mediated, at least in part, by stimulation of the central alpha-2 
adrenoceptors (Hayashi et al., 1991). 
The vagal activity plays a significant role in the antiarrhythmic action of 
dexmedetomidine. Indeed, this action seems to be mediated more by imidazoline receptors 
in the CNS than by alpha-2 adrenoceptors (Kamibayashi et al., 1995A & B), and this 
sustains a major interest for the preferential use of medetomidine and dexmedetomidine. 
 
2.5 Blood flow 
 
There is some evidence that medetomidine produces a redistribution of blood flow to 
preserve blood supply to vital organs (e.g. brain, heart, kidneys and liver), and reduces 
blood flow in less vital organs like skin, intestine, and skeletal muscles. A study on the 
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effects of a combination of medetomidine with butorphanol and midazolam, before 
isoflurane anaesthesia on renal cortical, intestinal, and muscle microvascular blood flow, 
showed a decrease in intestinal and skeletal blood flow, suggesting that this combination 
produced a redistribution of blood flow (Pypendop and Verstegen, 2000). 
In another study on the effects of dexmedetomidine on organ blood flow, results 
indicated preserved blood flow to the brain, heart, liver and kidneys, at the expense of less 
vital organs (Lawrence et al., 1996A). Renal blood flow was studied in a recent study in 
mice after radiocontrast-induced nephropathy, which demonstrated that alpha-2 agonists 
(dexmedetomidine and clonidine) preserved outer-medullary renal blood flow, thus 
improving outcomes after iodinated radiocontrast exposure (Billings et al., in press). 
A study was conducted to determine if medetomidine could be used to decrease 
intracranial pressure (by decreasing cerebral blood flow) prior to anaesthetic management 
of animals with intracranial lesions or increased intracranial pressure. It was concluded that 
medetomidine (30 µg/kg IV) did not change intracranial pressure despite its significant 
cardiovascular effects inducing cerebral blood flow decrease (Keegan et al., 1995). 
However, earlier studies showed that dexmedetomidine (10 µg/kg) reduces cerebral 
blood flow up to 50% in dogs, during halothane or isoflurane anaesthesia (Karlsson et al., 
1990; Zornow et al., 1990). It was found that dexmedetomidine had no effect on cerebral 
metabolic rate of oxygen. Furthermore, there was no evidence of global cerebral ischemia 
(Zornow et al., 1990). The cerebral vasoconstrictive effect, combined to the significant 
reduction of Minimal Alveolar Concentration (MAC) for halothane or isoflurane, indicates 
that dexmedetomidine might be useful if used as adjunct to inhalation anaesthetics during 
brain surgery, in situations where an increase in cerebral blood flow should be avoided 
(Karlsson et al., 1990). 
In light of these studies, alpha-2 agonists-induced blood flow reduction does not 
cause hypoperfusion of vital organs in healthy dogs (Murrell and Hellebrekers, 2005). 
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2.6 Oxygen delivery 
 
Earlier studies implied that alpha-2 stimulation plays an important role in myocardial 
ischemia induction. Further studies showed that myocardial energy requirement decreases 
at low concentrations of medetomidine, whereas moderate coronary vasoconstriction occurs 
with high concentrations (Flacke et al., 1993; Coughlan et al., 1992). Because lower doses 
of the alpha-2 agonist are currently used, the myocardial energy sparing effects are most 
likely preserved (Lawrence et al., 1996B). 
It seems likely that alpha-2 adrenergic coronary vasoconstriction could be overcome 
by metabolite-induced vasodilatation (a common control pathway of coronary blood flow), 
which preserves endocardial blood flow (Roekaerts et al., 1996). This was confirmed in 
conscious dogs (less susceptible to myocardial hypoxia than anesthetized animals) 
receiving a low dose of medetomidine, either as bolus (Schmeling, 1991) or as CRI 
(Grimm et al., 2005), giving evidence that the oxygen delivery still exceeds the oxygen 
consumption. In an isolated rat heart model, dexmedetomidine significantly decreased 
coronary blood flow and significantly decreased myocardial infarct size after 
ischemia/reperfusion (Okada et al., 2007). 
Cardiac output is one of the major determinants of peripheral oxygen delivery. 
Alpha-2 agonists reduce cardiac output thus decreasing tissue oxygen tension and, due to 
redistribution of blood flow the peripheral oxygen delivery particularly may decrease. This 
effect could theoretically result in more postoperative wound infections (Akça et al., 2002). 
Decreased peripheral blood flow and oxygen delivery have prompted studies on skin 
perfusion during flap implantations. A recent study showed that post-operative use of 
dexmedetomidine for deep sedation in a porcine model of musculocutaneous 
transplantation did not have deleterious effects on local perfusion or tissue metabolism in 
denervated musculocutaneous flaps (Nunes et al., 2007). 
Cyanosis is a frequently noticed effect of medetomidine in dogs and is thought to 
demonstrate poor oxygen delivery. However, the arterial oxygen tensions are not 
significantly changed and arterial oxygen saturation is usually above 95%. Cyanosis, 
following alpha-2 agonist administration, occurs due to increased oxygen extraction leading 
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to venous desaturation. Lower heart rate and slower blood flow through tissues allows more 
oxygen to be extracted (Paddleford and Harvey, 1999; England and Clarke, 1989; Lin et al., 
2008; Uilenreef et al., 2008). 
 
3.0 EFFECTS OF ANTICHOLINERGICS WITH ALPHA-2 AGONISTS 
 
The use of anticholinergics to prevent bradycardia and atrioventricular blockade induced by 
preoperative administration of selective alpha-2 agonists is controversial (Dart, 1999). 
Antimuscarinic (anticholinergic) pre-medication has been used with alpha-2 agonists to 
prevent bradyarrhythmias. However, the antimuscarinic-induced increase in heart rate does 
not ensure an improvement of the overall cardiac performance. It may actually potentiate 
alpha-2-adrenoceptor-mediated hypertension, produce tachycardia, and increase myocardial 
work (Vainio and Palmu, 1989B; Alibhai et al., 1996; Ko et al., 2001A; Sinclair et al., 
2003A). 
Cardiovascular effects after alpha-2-adrenergic agonist administration are advocated 
to be inseparable from sedative and analgesic effects. It has even been suggested that they 
can be beneficial for healthy animals and should not be prevented/treated. Bradycardia, 
after alpha-2 agonist administration, is initially a physiological vagal response to increased 
blood pressure and vasoconstriction. After this initial response, a central origin response is 
seen (Maze and Tranquilli, 1991). 
Anticholinergics used to increase heart rate when necessary in combination with 
sedative drugs, should not be used with alpha-2 agonists. Even though they may prevent 
medetomidine-induced bradycardia, this inhibitory effect is transient (Vainio and Palmu, 
1989B). 
In a study with romifidine (another potent and selective alpha-2 agonist) in dogs, 
concurrent use of anticholinergic (glycopyrrolate) was associated with a higher frequency 
of dysrhythmias. Its use was therefore not recommended. Prior or concurrent administration 
of glycopyrrolate produces increased myocardial workload and oxygen demand (Sinclair et 
al., 2002). Pre-treatment with glycopyrrolate actually appeared to be detrimental to 
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cardiovascular performance, and when used with romifidine, they produced additive 
adverse effects on myocardial function in conscious dogs (Sinclair et al., 2003A).  
It has been suggested that when the heart is forced to beat more frequently with the 
use of anticholinergics, the myocardium may suffer from a failure to meet its oxygen 
demand (Lemke et al., 1993C; Paddleford and Harvey, 1999) which may lead to 
myocardial ischemia and promote arrhythmias. Furthermore, the bradycardia produced by 
alpha-2 agonists may be nonresponsive to anticholinergic drugs. The use of anticholinergics 
in animals receiving alpha-2-agonists may promote fatal ventricular arrhythmias (Short, 
1991; Tranquilli and Benson, 1992; Klide, 1992). 
In addition, dexmedetomidine has antiarrhythmic effects, presumably via 
imidazoline receptors. These effects are associated with vagal stimulation. This 
demonstrates another reason not to combine them to antimuscarinic drugs (also called 
vagolytic agents) which would inhibit the pro-vagal antiarrhythmic effects of certain alpha-
2 agonists (Murrell and Hellebrekers, 2005). A meta-analysis of human trials found that co-
administration of an anticholinergic with dexmedetomidine did not significantly decrease 
the incidence of bradycardia. In fact, their use may decrease the potential vagally-mediated 
cardioprotective effects of dexmedetomidine (Biccard et al., 2008).  
For the reasons listed above, it has been suggested that the safest remedy for life-
threatening bradyarrhythmias is reversible with alpha-2 antagonists (Short, 1991; Pypendop 
and Verstegen, 1998). 
 
 
4.0 RESPIRATORY EFFECTS 
 
Medetomidine produces a slight depression of respiratory rate. This reduction in respiratory 
frequency is probably centrally mediated (Vainio, 1990). Intravenous dexmedetomidine in 
dogs was shown to induce a potent dose-dependent suppression in the slope of the CO2 
response curve, a significant decrease in resting respiratory rate, but no change in resting 
end-tidal CO2 (Sabbe et al., 1994). 
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Alpha-2 agonists do not induce profound respiratory depression, a common side 
effect associated with opioids. Although respiratory rate and minute ventilation decrease 
with medetomidine, arterial blood gas values do not usually change significantly (Short, 
1992; Pypendop et al., 1996). Arterial partial pressure of CO2 usually remains at normal 
levels or slightly lower and pH usually stays within acceptable range. 
In a study on the effects of medetomidine on ventilatory drive in dogs, it was found 
that medetomidine produces less depression on ventilatory drive than isoflurane (Bloor et 
al., 1989). In spite of similar receptor locations and functions with opioids, medetomidine 
does not affect ventilatory drive by the same mechanism. The effects of narcotics on the 
ventilatory drive are profound at drug levels required during anaesthesia. In comparison to 
the narcotic class, medetomidine has anaesthetic qualities with far less respiratory 
depression (Bloor et al., 1989). 
However, in a more recent study, it was concluded that IV administration of 
medetomidine at dosages of 5 or 10 µg/kg IV decreases respiratory rate, minute volume, 
and respiratory drive in conscious dogs. Thus, medetomidine should be used cautiously in 
dogs with pre-existing respiratory dysfunction, especially when given concurrently with 
drugs known to depress respiration, a common procedure during perianaesthetic period 
(Lerche and Muir, 2004). 
In addition to other ventilatory effects, IV administration of dexmedetomidine in 
dogs was shown to prevent histamine-induced bronchoconstriction (Groeben et al., 2004). 
The arterial partial oxygen tension (PaO2) may decrease during the peak effect of 
medetomidine, because of decreased ventilation associated with an increase in PaCO2. 
However, this corresponds to the period of slowest heart rates with a resulting decrease in 
whole body oxygen demand and thus adequate oxygenation of the tissues is usually 
maintained (Pettifer and Dyson, 1993). 
When used in combination with opioids and benzodiazepines to produce profound 
anaesthesia, medetomidine may increase the respiratory depression primarily caused by 
opioids, and will lead to hypoxia, hypoxaemia (Dart, 1999), as well as compromised tissue 
perfusion (Pypendop et al., 1996; Pypendop and Verstegen, 1999). Because of these 
additive or synergistic side effects, oxygen supplementation should be provided during 
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anaesthesia and is especially important for compromised patients. In addition, ventilatory 
support should be provided when using these combinations (Pypendop and Verstegen, 
1999). 
 
5.0 METABOLIC AND OTHER EFFECTS 
 
5.1 Effects on blood glucose level 
 
Medetomidine inhibits insulin release, and increases blood glucose levels (Short, 1992). 
While inhibition of insulin release is rapid and significant after medetomidine 
administration (10 or 20 µg/kg IV), lasting for about 2 hours, the increase in plasma 
glucose concentration has been found to be less dramatic, slow, and non-significant with 
medetomidine (because of its higher alpha-2 selectivity), when compared to xylazine 
(Burton et al., 1997). Mean plasma glucose concentration tended to be higher after 
medetomidine treatment (10 or 20 µg/kg IV) than with placebo (0.9% sodium chloride), but 
no significant differences between treatments were demonstrated, and plasma 
concentrations remained within normal physiologic range for dogs. 
Another study comparing metabolic and neurohormonal effects of medetomidine 
and xylazine (both drugs at several different dose levels, given IM) found that both drugs 
increased blood glucose levels, although medetomidine far less than xylazine. In addition, 
medetomidine did not show a dose-dependent increase in blood glucose levels, contrary to 
xylazine (Ambrisko and Hikasa, 2002). Moreover, it was found that plasma peak level 
following medetomidine administration shifted further in time as the dosage increased. 
Namely, glucose peaked 2 h after 20 µg/kg IM medetomidine, 3 h after 40 µg/kg, and 4 h 
after 80 µg/kg. 
By contrast, in another study with dexmedetomidine (5 µg/kg IV), plasma glucose 
concentrations were substantially decreased 30 minutes after administration of 
dexmedetomidine (Raekallio et al., 2005). Such a finding had never been described in dogs 
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before. However, it has been described in children after clonidine treatment. In the canine 
study, plasma glucose levels returned to baseline values within 90 minutes, after 
dexmedetomidine administration. It was suggested that with a longer follow-up period, 
glucose peak concentrations may have been seen. 
 
5.2 Effects on growth hormone level 
 
Medetomidine increases growth hormone levels in plasma by potentiating its secretion 
(Short, 1992; Hayashi and Maze, 1993). However, at clinical doses, this effect is not likely 
to have serious consequences (Hayashi and Maze, 1993; Sinclair, 2003B). 
 
5.3 Effects on urination 
 
Medetomidine induces a diuretic effect that last up to 4 hours (with dosages of 10 or 20 
µg/kg IV) in dogs. The most probable mechanism to cause this increased production of 
urine is the interference with ADH-mediated water permeability in the renal tubules and 
collecting ducts (Burton et al., 1998; Crighton, 1990). This mechanism has been reported 
after administration of other alpha-2 agonists in rats. 
It has been suggested that medetomidine, like xylazine, increases plasma and urine 
glucose levels, which then causes osmotic diuresis. However, other studies inferred that 
medetomidine has a very small effect on plasma glucose concentration (Burton et al., 1997) 
and a recent study showed that dexmedetomidine decreased plasma glucose concentrations 
(Raekallio et al., 2005). These findings suggest that hyperglycemia and glucosuria, causing 
osmotic diuresis, are probably not appreciable factors causing voluminous urination in dogs 
after medetomidine/dexmedetomidine administration. 
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5.4 Effects on intestine 
 
Medetomidine reduced intestinal motility and gut sounds in small animals (Dart, 1999). In 
fasted dogs, medetomidine (30 µg/kg IV) disrupted the migrating myoelectric complex 
pattern of the small intestine for approximately 2 hours. The same dose inhibited colonic 
motility in fasted dogs, although medetomidine-induced inhibition was preceded by a short 
period of increased muscle tone. In fed dogs, medetomidine (30 µg/kg IV) induced a strong 
increase of the proximal colon tone, while the activity of the medium and distal colon was 
completely suppressed (Maugeri et al., 1994).  
Administration of medetomidine (40 µg/kg IM) significantly inhibited the motility 
of the gastric antrum, duodenum, mid-jejunum, and ileum. The inhibition of motility was 
longer in the gastric antrum and the duodenum than in the mid-jejunum and ileum. 
Medetomidine also inhibited gastric contractions associated with gastrin secretion 
(Nakamura et al., 1997). 
This inhibitory action on intestinal motility is believed to be mediated via peripheral 
alpha-2 receptors rather than central receptors. In addition, this inhibitory action outlasts the 
duration of sedation (Hall and Clarke, 1991; Cullen, 1996; Maugeri et al., 1994). The 
effects of medetomidine on gastric emptying have been shown to be weaker and of shorter 
duration than those of morphine (Tobias, 2007). 
 
5.5 Emetic effects 
 
There is an emetic effect in dogs and cats particularly after IM administration. Vomiting 
occurs in 5-20 % of dogs and in most cats. In another study, vomiting occurred in 17 % of 
dogs regardless of dose studied; however, none of the dogs receiving optimal dosage (in 
that study 1000 µg/m2 IM) vomited (Hamlin and Bernarski, 1989). Normally vomiting is 
not a problem, but the potential for development of aspiration pneumonia exists. Moreover, 
vomiting also increases intracranial and intraocular pressure, which may be a problem for 
some patients with cerebral or ocular injury or disease (Lemke, 2004A). 
  
24
 
 
5.6 Hypothermia 
  
A decrease in body temperature has been associated with alpha-2 agonist administration. 
The temperature reduction may be centrally mediated, with specific CNS depression, 
and/or in combination with non-specific depression of general metabolism and reduction in 
muscular activity (Virtanen, 1989; Verstegen and Petcho, 1993). In addition, it has been 
postulated that a direct action on noradrenergic receptors in the hypothalamus by alpha-2 
agonists may cause hypothermia in a dose-dependent manner (Cullen, 1996). After IV, and 
to a lesser extent, epidural dexmedetomidine administration, a dose dependent reduction in 
core body temperature was observed (Sabbe et al., 1994). However, in some studies with 
medetomidine only slight reductions of rectal temperature were observed (Pypendop and 
Verstegen, 1998; Pettifer and Dyson, 1993; Verstegen and Petcho, 1993).  
In contrast, alpha-2 agonists may allow for better maintenance of body temperature 
due to the peripheral vasoconstriction and central redistribution of blood, with a consequent 
reduction in cutaneous heat losses compared to other sedatives and anaesthetic agents that 
induce vasodilatation (Lemke, 2004A). 
 
5.7 Effects on the uterus 
 
Alpha-2 agonists were found to increase the contractility of the pregnant and nonpregnant 
uterus in some studies. In a canine study, it was found that the effect of medetomidine 
depends to a higher degree on the level of steroid hormones. A rise in oestrogen levels 
increases the sensitivity of alpha-2-adrenoceptors, while a high level of progesterone during 
pregnancy stimulates the sensitivity of beta-adrenoceptors and decreases the contractility of 
the uterus. Medetomidine does not appear to promote abortion in pregnant dogs (Jedruch et 
al., 1989). 
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5.8 Neuroprotection 
 
A possible neuroprotective effect of alpha-2 agonists has been suggested. The neurologic 
outcome after several types of cerebral ischemia may be improved with the use of alpha-2 
agonists (Iida et al., 2006) yet the underlying mechanisms still remain unclear. It was 
suggested that the alpha-2 agonist-induced sympathetic blockade and/or decreased release 
of excitatory neurotransmitters (such as glutamate) may account for the neuroprotective 
effects during and after ischemia. It has also been postulated that neuroprotection may be 
mediated by a reduction in caspase-3 expression (a pro-apoptotic factor) and an increased 
expression of active (autophosphorylated) focal adhesion kinase, a non-receptor tyrosine 
kinase that plays a role in cellular plasticity and survival (Dahmani et al., 2005; Tobias, 
2007). In addition, the cerebrovascular and cerebral metabolic effects of of alpha-2 agonists 
may contribute, in part, to the neuroprotective action. Conflicting evidence exists for this 
action, since some rodent studies have demonstrated it (Kuhmonen et al., 1997; Jolkkonen 
et al., 1999), whereas studies in dogs (Iida et al., 2006) and humans lack this evidence 
(Sulemanji et al., 2007). 
 
5.9 Effects on adrenocortical function, inflammatory response, and neuromuscular 
blockade 
 
Compounds that contain an imidazoline ring (etomidate, medetomidine, dexmedetomidine) 
can inhibit hydroxylase enzymes involved in the production of adrenocorticosteroids 
(Tobias, 2007). There was no evidence of depressed adrenocortical function with 
dexmedetomidine concentrations used clinically in human patients, to the extent that 
occurs, for example, with etomidate. However, higher doses can inhibit steroidogenesis. 
 Dexmedetomidine decreased interleukin-6 levels from baseline (Nishina et al., 
1999). It also blunts the systemic inflammatory response during endotoxaemia (Taniguchi 
et al., 2004). 
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 Effects of dexmedetomidine on neuromuscular blockade function have been 
studied. There was no change when vecuronium was used. It induced a significant decrease 
in the height of the first twitch of train-of-four and an increase in neuromuscular blocking 
agent (rocuronium) plasma concentration. There was no evidence of direct effects on the 
neuromuscular junction, and these effects seemed related to alterations of pharmacokinetics 
of rocuronium (Talke et al., 1999). 
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6.0 ANALGESIA 
 
Pain is defined as a subjective experience consisting of two components: perception of pain 
(which includes unpleasant sensory and emotional experiences) and reaction to pain, which 
usually results in a reaction to avoid further pain sensation. 
In sedated animals the sensory message of a painful event relayed to the CNS may 
be unchanged, but due to the sedative effect, the emotional experience of pain feeling may 
be suppressed and the animal may therefore not react as vigorously as an unsedated animal. 
When analgesic effects of a sedative drug are studied, it is very difficult to 
distinguish between true sedative and true analgesic effect (Vainio et al., 1989C). However, 
there is clear evidence (based on analgiometric measurement techniques) that 
medetomidine and other alpha-2 agonists are highly potent analgesic agents.  
Some observations from the use of medetomidine in humans at sedative doses are 
accompanied by the attenuation of the emotional experience of pain, although not its 
intensity. However, this may further complicate pain studies since the investigational 
models of pain may not fully reflect the patients complete clinical experience. Moreover, 
amelioration of pain experience is a valid goal, whether it is attributed to direct analgesic 
effects, sedation, or other processes (Aantaa and Jalonen, 2006). 
 
6.1 Pain mediating alpha-2 receptors 
 
Sedative and anxiolytic effects of alpha-2 agonists are mediated by activation of supraspinal 
receptors located in the pons (locus ceruleus). Analgesic effects are mediated by activation 
of receptors located in the dorsal horn of the spinal cord. However, there is also evidence 
that the supraspinal receptors located in the pons also play a prominent role in descending 
modulation of nociceptive pathway (Lemke, 2004B; Cullen, 1996; Ossipov et al., 1990; 
Stenberg, 1989). Previous animal studies have demonstrated a powerful antinociceptive 
effect following spinal administration of alpha-2 agonists. This effect, mediated at the spinal 
level is present after systemic, epidural, and intrathecal administration. However, the time 
  
28
 
to reach the peak effect and the duration of the action depend on dose and route of 
administration (Sabbe et al., 1994). Recent evidence from an animal model suggests that 
dexmedetomidine hyperpolarizes the membrane potential of substantia gelatinosa 
(superficial dorsal horn, especially lamina II) neurons by G-protein-mediated activation of 
potassium channels through postsynaptic alpha-2A and alpha-2C-adrenoceptors. This action 
may contribute to its antinociceptive action in the spinal cord (Ishii et al., 2008). 
 
6.2 Similarities between alpha-2 receptor and opioid receptor mediated analgesia 
 
In pain modulation, there are interactions between opioid and alpha-2 receptors in the brain 
and spinal cord. Alpha-2 receptor stimulation produces analgesic and sedative effects 
similar to those of opioid receptor stimulation in the CNS (Paddleford and Harvey, 1999). 
First, alpha-2 and opioid receptors are found in similar regions of the brain and on 
some of the same neurons. Both receptors are found in locus ceruleus (LC) and in the 
dorsal horn of the spinal cord (Paddleford and Harvey, 1999).  
Second, these receptors have similar physiological influences. They suppress 
nociceptive signals with a multifactorial action on pain pathways: 1) by inhibiting 
neurotransmitter release from primary afferent fibers to second order neurons; 2) by 
affecting pre- and post-synaptic modulation of nociceptive signals in dorsal horn; 3) by 
influencing descending modulatory systems from the brainstem; 4) or by altering ascending 
modulation of nociceptive signals in the diencephalon and limbic areas (Murrell and 
Hellebrekers, 2005).  
Third, these receptors share common molecular machinery: both receptor types are 
activated via stimulation of the pertussis toxin-sensitive G-proteins (Gi and/or Go) on the 
cell membrane. Adenylate cyclase is inhibited, resulting in the reduction of the intracellular 
cAMP content. This leads to the opening of potassium channels, causing the cell to loose 
potassium and inhibition of the voltage-gated calcium channels. Calcium is blocked and 
noradrenaline release is inhibited. The cell becomes hyperpolarized (more negatively 
charged), making the cell unresponsive to excitatory input; thus, the transmission pathway 
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is blocked (Fukuda, 2005; Paddleford and Harvey, 1999; Maze and Tranquilli, 1991; 
Ossipov et al., 1990). 
Consequently, the alpha-2 agonists and mu-opioids produce analgesia by similar 
mechanisms. 
 
6.3 Clinical implications in pain management 
 
Alpha-2 agonists are highly effective to treat short-term pain in humans. They are used 
intraoperatively and postoperatively. Using alpha-2 agonists instead of opioids allows 
avoiding problems like respiratory depression, pruritus, urinary retention, and abuse 
liability. Using alpha-2 agonists together with opioids reduces opioid requirements 
(Kamibayashi et al., 2000). When using a combination of alpha-2 agonist and opioid, the 
doses may be reduced and consequently the side effects of both drugs are reduced. 
Decreased doses of opioids induce less respiratory depression, while alpha-2 agonists 
induce less cardiovascular depression (Ossipov et al., 1990). 
In studies with rats, alpha-2 agonists also have some advantages against neuropathic 
pain. Alpha-2 agonists may attenuate or even reverse the allodynia that occurs in 
neuropathic pain. Neuropathic pain is highly difficult to manage with other modalities such 
as opioids therefore alpha-2 agonists may have a potential to treat opioid-resistant pain 
(Murrell and Hellebrekers, 2005). 
Increasing evidence from human medicine, with the use of dexmedetomidine 
infusion, seems to imply that analgesic efficacy for postoperative pain may only be 
moderate, with currently recommended doses (Gomez-Vasquez et al., 2007). However this 
moderate analgesic effect in conjunction with the anxiolytic and sedative effects may 
attenuate the unpleasantness of pain (Aantaa and Jalonen, 2006). 
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6.4 Alpha-2 agonists induce analgesia dose-dependently 
 
Medetomidine and dexmedetomidine in dogs showed that the degree of analgesia was 
significantly dose-dependent (Kuusela et al., 2001). The analgesic effect of medetomidine 
in the dog was suggested to begin at plasma levels of 1-5 ng/ml (Salonen, 1992). By 
contrast, in a study where analgesia was assessed by limb withdrawal to toe pinching, 
analgesia was already considered practically nonexistent with a medetomidine plasma level 
as high as 9.5 ng/ml (Kuusela et al., 2000). In addition, analgesia with pure 
dexmedetomidine lasted longer than with the corresponding level of racemic 
medetomidine, suggesting greater potency of dexmedetomidine in dogs (Kuusela et al., 
2000). 
Assessment of the analgesic effect based on the pinprick and pedal reflex tests 
showed that analgesia observed in dogs was dose-dependent in strength at dosages of 10-80 
µg/kg IM. Slight analgesia was observed at 10-30 µg/kg IM and was most prominent 
between 40 and 80 µg/kg IM. Good analgesia lasted 1 hour at 40 µg/kg IM (Vainio et al., 
1986). Using analgesiometric technique, after a single dose of dexmedetomidine (20 
µg/kg), analgesia was suggested to last for about one hour (Murrell and Hellebrekers, 
2005). Time to reach maximal effect and duration of analgesia (evaluated by skin twitch) 
were dependent of the dose and the route of administration in dogs following IV, epidural, 
and intrathecal administration of dexmedetomidine (Sabbe et al., 1994). After IV 
administration of 10 µg/kg dexmedetomidine, the analgesic effect began within 3 minutes 
and lasted 90 minutes. Analgesic effect appears to be more potent and to last longer after 
epidural administration, with less systemic redistribution providing less systemic 
(hemodynamic and neurobehavioral) effects. 
Alpha-2 agonists were shown to produce excellent sedation, lasting longer than with 
the effective analgesia (Short, 1992). This was important when medetomidine was used for 
premedication and the analgesic effect was needed for the entire duration of the procedure. 
Thus readministration of the drug might be needed to prolong the analgesic effect (Murrell 
and Hellebrekers, 2005). 
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 Based on human studies, there are conflicting results on analgesic efficacy of 
dexmedetomidine. While some have reported good peri-operative analgesia and reduction 
of the opioid consumption (Tufanogullari et al., 2008), others have reported only moderate 
analgesic effects in the early postoperative period (Gomez-Vazquez et al., 2007). This 
discrepancy may be related to dose regimen given as well as invasiveness of the surgery. 
Healthy adults for elective orthopaedic surgery appear to benefit less from the analgesic 
effect of dexmedetomidine. In addition, the induced sedation in this context may not be 
desirable. 
 
7.0 SEDATION, ANAESTHETIC SPARING, AND SYNERGISTIC OR ADDITIVE 
EFFECTS WITH OTHER DRUGS 
 
The pharmacological sedation induced by medetomidine or dexmedetomidine via their 
action on the locus coeruleus of the brain stem has been demonstrated to closely resemble 
physiological non-REM sleep (Huupponen et al., 2008). Endogenous sleep pathways may 
be involved in dexmedetomidine-induced sedation (Nelson et al., 2003). 
When medetomidine or detomidine were used as premedication, there was a major 
reduction in any subsequent anaesthetic requirements (Ewing et al., 1993, Vainio, 1991, 
Young et al., 1990). This supports the evidence of the sedative and analgesic properties of 
medetomidine and detomidine (Short, 1992). This anesthetic sparing effect was found to be 
significantly dependent of medetomidine dose level (Kuusela et al., 2001). 
Synergistic or additive effects may be observed when medetomidine or 
dexmedetomidine is combined with other agents (tranquilizers, opioids, injectable 
anaesthetics, and inhalant anaesthetics) (Verstegen and Petcho, 1993; Hammond and 
England, 1994).  
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7.1 Synergistic and/or additive effects in combinations 
 
Combinations of opioids and alpha-2 agonists can result in profound sedation and analgesia 
in dogs (Short, 1992). Evidence of synergistic effects of alpha-2 agonists with opioids was 
found in studies with mice and rats, and more recently in studies in dogs and cats. 
In a study from Ossipov et al. (1990), evidence was found for synergy of 
medetomidine with opioids (fentanyl, morphine, and meperidine) after intrathecal 
administration of these combinations and additive effects of these combinations after IV 
administration in rats (Ossipov et al., 1990). Another study using an alpha-2 agonist, 
moxonidine, demonstrated spinal antinociception and synergy with opioids in the mouse 
spinal cord (Fairbanks et al., 2002). 
In addition, a study in cats has shown the ability of subanalgesic doses of the alpha-2 
agonist, clonidine, to have an additive or synergistic effect on analgesia produced by 
opiates, when both drugs were administered epidurally or intrathecally (Omote et al., 
1991). 
In a study on epidurally administered morphine (0.11 mg/kg) and medetomidine (5 
µg/kg) in dogs, a simultaneous administration of these drugs suggested an additive and 
even synergistic interaction between these two agents when administered epidurally 
(Branson et al., 1993). The synergistic effects in dogs seem to be restricted to epidural or 
intrathecal administration (Ossipov et al., 1990; Branson et al., 1993). 
This synergy between alpha-2 and opiate agonists was suggested to be caused by the 
activation of alpha-2 adrenoceptors on opiate-containing interneurons. This would result in 
increased release of opiate peptides (Omote et al., 1991; Branson et al., 1993). The 
therapeutic advantages of opioids and medetomidine combinations are envisioned as 
increased analgesia with reduced respiratory and cardiovascular involvement by decreasing 
dose requirements of both drugs. 
Studies with combinations of medetomidine and opioids such as hydromorphone or 
butorphanol have suggested 1) improved analgesia (Grimm et al., 2000) and 2) the sedation 
prior to induction, may facilitate orotracheal intubation, improve quality of anesthesia, and 
have similar cardiovascular effects when compared to medetomidine alone (Kuo and 
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Keegan, 2004; Muir et al., 1999). Contrary to these findings a study using a combination of 
medetomidine (10 µg/kg) and butorphanol (0.2 µg/kg) failed to demonstrate any 
advantages when compared to 40 µg/kg of medetomidine given alone (Ko et al., 1996). 
However, in a more recent study, the same author concluded that a combination of 
medetomidine (30 µg/kg) with butorphanol (0.2 mg/kg) or ketamine (3 mg/kg) resulted in a 
more reliable and uniform sedation in dogs, when compared to medetomidine (30 µg/kg) 
alone (Ko et al., 2000B). 
There is also evidence that medetomidine prevents or blunts stress-related 
neurohormonal changes produced by opioids or ketamine administration in dogs. This 
supports the use of medetomidine in combination for sedation or anaesthesia of healthy 
dogs (Ambrisko et al., 2005).  
Combining low doses of alpha-2-, opioid-, and benzodiazepine-agonists in dogs, 
resulted in a synergistic CNS depressant response, while minimizing the undesirable side 
effects of these three classes of drugs (Verstegen and Petcho, 1993; Paddleford and Harvey, 
1999). 
 
7.2 Anaesthetic sparing effects 
 
Alpha-2 agonists have highly potent anaesthetic sparing effects. Medetomidine can reduce 
propofol dosage requirements by 75 % in dogs (Short, 1992; Vainio, 1991). Medetomidine 
also produced a dose-dependent reduction of dose requirements of propofol for induction. 
With a dose 5 µg/kg IM of medetomidine, the mean induction dose of propofol was 
decreased by more than 50% from 6.0 to 2.86 mg/kg. With medetomidine doses of 10, 20, 
and 40 µg/kg IM the mean induction dose of propofol was decreased to 1.44, 1.12, and 0.77 
mg/kg, respectively (Hammond and England, 1994). 
Medetomidine extends the duration of propofol anaesthesia and provides post-
anaesthetic sedation and analgesia (Bulafari et al., 1996). In addition, propofol infusion in 
medetomidine premedicated dogs was suggested to alleviate medetomidine-induced 
vasoconstriction (Thurmon et al., 1994). In a previous study by Vainio (1991), propofol 
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also had a positive chronotropic effect after medetomidine premedication, alleviating the 
medetomidine-induced negative chronotropic effect. 
In a human study, dexmedetomidine reaching plasma concentrations approximately 
0.66 ng/ml, reduced propofol concentrations required for sedation and for suppression of 
motor response to electrical stimulation by approximately 65-80%, and 40% respectively 
(Dutta et al., 2001). 
Medetomidine markedly reduced thiopentone dose required for intubation in a dose-
dependent manner (Young et al., 1990, Cullen, 1999, Ko et al., 2000A). In a study by 
Young et al., (1990) the barbiturate sparing effect of medetomidine was significant at all 
three dose rates examined. The mean doses of 1.25% thiopentone required for intubation 
were 6.9, 4.5, and 2.4 mg/kg with medetomidine at dose levels 10, 20, and 40 µg/kg IM, 
respectively. At high medetomidine dosages (40 µg/kg), some dogs can even be intubated 
with medetomidine alone (Young et al., 1990). In another study, after 40 µg/kg 
medetomidine, the thiopental induction dose was 4.4 mg/kg compared with 14.8 mg/kg 
without medetomidine (Ko et al., 2000A). 
Medetomidine, given at 40 µg/kg IM, reduced halothane dose requirements by at 
least 30 %, compared to a dose level of 20 µg/kg IM in a canine study (Räihä et al., 
1989B). In a study with halothane, the dosage of medetomidine 10 µg/kg IM had a 
halothane sparing effect comparable to other sedatives (acepromazine and meperidine) 
while a dose level of 40 µg/kg IM of medetomidine showed a clear decrease in halothane 
consumption (Räihä et al., 1989A). 
In a study with rats, dexmedetomidine decreased dramatically the MAC of 
halothane in a dose dependent manner (doses of 10, 30, and 100 µg/kg IP) such that at 100 
µg/kg, halothane could even be discontinued for up to 30 minutes without eliciting a 
purposeful response to tail-clamping (Segal et al., 1989). 
In a study with dogs using three dosages of medetomidine (1, 3, and 10 µg/kg 
administration via right atrial port over 15 minutes) the MAC for halothane significantly 
decreased in a dose-dependent manner. Following medetomidine administration, the MAC 
for halothane decreased progressively and at the highest dosage (10 µg/kg), the anaesthetic 
requirement decreased by 90 % (Vickery and Maze, 1989). 
  
35
 
In addition, medetomidine at 30 µg/kg IV reduced isoflurane maintenance 
requirements by 47 % (Ewing et al., 1993). Moreover, dexmedetomidine at 20 µg/kg IV 
reduced isoflurane MAC maximally (89 %) 30 minutes after the injection (Bloor et al., 
1992). In a recent study using three dosages (0.1, 0.5, and 3.0 µg/kg/h) of continuous 
infusion of dexmedetomidine in dogs, the MAC reduction was found to increase dose-
dependently (Pascoe et al., 2006). Significant decreases in MAC were found with 0.5 and 
3.0 µg/kg/h doses (decreases of 18 % and 59 %, respectively). 
Medetomidine premedication is also often used prior to ketamine administration, an 
injectable dissociative anaesthetic. This combination characterized by fewer bradycardic 
effects, induces more adverse effects as well as an inferior overall quality of anaesthesia 
and recovery than the medetomidine-propofol combination (Hellebrekers, 1998). In 
addition, respiratory depression is usually more profound when dogs are given ketamine 
(Ko et al., 2001B). 
When alpha-2 agonists are used as premedication, it is necessary to remember that 
due to their cardiovascular effects (decreased blood flow), the distribution of other 
anaesthetic drugs is slower than expected and it is thus important to wait before re-
administration of other anaesthetic drugs (propofol, barbiturates, etc.). The uptake of 
inhaled anaesthetics is also delayed, meaning that an adequate time should be allowed to 
permit stabilization. Failure to recognize these factors may lead to overdosing of other 
anaesthetic agents (Manners, 1990; Short, 1992; Hellebrekers et al., 1998; Lemke, 2004A).  
Because all general anaesthetics (thiopental, propofol, halothane, isoflurane, etc.) 
have dramatic effects on myocardial function and a very narrow therapeutic range, the dose 
reduction achieved by administering alpha-2 agonists preoperatively reduces the adverse 
cardiovascular effects associated with administration of most general anaesthetics. For 
example, preoperative medetomidine administration counteracts the cardiovascular effects 
of isoflurane, first, by reducing the amount of isoflurane needed and, then, by restoring 
vascular tone (vasoconstriction effect of alpha-2 agonists) (Lemke, 2004A). 
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8.0 CLINICAL USE 
 
Alpha-2 agonists have been used alone for minor procedures. They are not regarded as 
anaesthetics; therefore, additional agents (local or general anaesthetics) are needed for 
surgery. Medetomidine is a highly potent sedative and analgesic agent for clinical use. 
Relatively high doses of medetomidine alone suffice for examination, clinical procedures, 
and simple surgical operations in dogs (Vähä-Vahe 1989B). However, low doses and 
combination with other analgesic and anaesthetic agents to produce balanced anaesthesia 
and analgesia are preferred. 
 
8.1 Chemical restraint and sedation 
 
Alpha-2 agonists are useful for chemical restraint alone or in combination with opioids and 
benzodiazepines, and are reversible with alpha-2 antagonist (Short, 1992). Because 
medetomidine and dexmedetomidine provide rapid and completely reversible sedation with 
analgesia, along with almost no respiratory depression, these agents may provide increased 
patient safety in certain situations (Talke, 1998). 
 Administration of a moderate dosage of medetomidine (5 µg/kg IV) provided a 
useful adjunct to diazepam-ketamine induced anaesthesia in dogs. It improves the quality of 
anaesthetic induction, ease of endotracheal intubation, and extends the duration of analgesia 
and lateral recumbency in anaesthetized dogs (Ko et al., 1998). 
 
8.2 Premedication 
 
Medetomidine used as premedication (at dosage levels of 1000 or 1500 µg/m2, equivalent 
to 40 µg/kg or 60 µg/kg for a 25-kg dog, respectively), provided a good basis for 
anaesthesia (in terms of sedation and hypnosis) and satisfactory analgesia for surgical 
intervention. Premedication was achieved reliably with medetomidine, and provided an 
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uneventful and stress-free preparation for surgery and anaesthesia induction. (Hellebrekers 
and Sap, 1997). 
Several studies have found that medetomidine is a good premedication to be used 
before induction (and maintenance) of anaesthesia by propofol (Hellebrekers and Sap, 
1997; Thurmon et al., 1994; Vainio, 1991). 
 
8.3 Analgesic and anaesthetic adjuvant to reduce perioperative stress and increase 
patient safety 
 
Medetomidine and dexmedetomidine have been shown to control the stress response 
induced by anaesthesia and surgery during the perioperative period. They reduced 
perioperative levels of stress-related hormones (Väisänen et al., 2002).  
In humans dexmedetomidine attenuated increases in heart rate and plasma 
norepinephrine concentrations during emergence from anaesthesia (Talke et al., 2000); 
Moreover, dexmedetomidine seemed to conceal stress effects of anaesthesia during 
recovery (Kuusela et al., 2003) in dogs. These findings have increased interest in use of 
alpha-2 agonists as preanaesthetic to promote balanced anaesthesia and minimize overall 
stress response (Ambrisko et al., 2005, Väisänen et al., 2002, Benson et al., 2000). 
Medetomidine premedication in combination provides safer anaesthesia by lowering 
the dose of other sedative, analgesic and anaesthetic agents. Furthermore, when used in 
combination the dose requirement of medetomidine itself is decreased, adding to the safety 
of the anaesthesia. 
As adjuncts to general anaesthetics, alpha-2 agonists have a nearly ideal 
pharmacodynamic profile in dogs. In addition to providing sedation, analgesia, and muscle 
relaxation, they produce substantial reduction in the amount of injectable and inhalational 
anaesthetic requirements and also attenuate the sympathetic activity and stress response to 
surgical trauma by reducing catecholamine and cortisol levels postoperatively (Benson et 
al., 2000, Ko et al., 2000A, Väisänen et al., 2002, Talke et al., 1997). 
Alpha-2 agonists have their place in controlling the emergence from anaesthesia. 
During this phase, patients may benefit from the sedative, anxiolytic, and analgesic effects 
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and attenuation of the hemodynamic disturbances due to increased sympathetic drive. In 
addition, dexmedetomidine is used to control and treat opioid withdrawal after prolonged 
use of opioids and benzodiazepines (Tobias, 2006). A significant reduction in the incidence 
of delirium with dexmedetomidine after surgery in humans has been documented. 
Prevention of shivering, which has deleterious influences including increased oxygen 
consumption and potentially increased demand on myocardial capacity was also reported 
(Aantaa and Jalonen, 2006). 
 
8.4 Side effects 
 
Side effects (other than cardiovascular) reported after medetomidine use were almost 
exclusively limited to vomiting and muscle jerking in dogs (Vähä-Vahe, 1989A). However, 
vomiting may sometimes be an advantage before surgery if owners have failed to fast their 
dogs prior to sedation.  
Other side effects following medetomidine administration include cyanotic or pale 
mucous membranes, irregular breathing pattern, squalling at injection, diarrhea, panting, 
restlessness, and collapse. 
 
8.5 Failures 
 
Stress, excitement or pain may increase endogenic catecholamine levels interfering with 
smooth sedation. When possible, a calm and gentle handling of the animal during 
administration of drug is desirable. Sedation is more effective in quiet areas without 
environmental stimulation (Short, 1992). 
Cardiac or respiratory disorders, obesity or cachexia, may influence levels of 
sedation. Very young and very old animals usually need a lower dose of drug to achieve 
sedation than what would be predicted from their bodyweight alone. Small dogs seem to 
need higher doses of medetomidine per kilo bodyweight to obtain an equal effect, 
compared to large dogs (Vähä-Vahe, 1989A). 
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If the route of administration is IM or SC, sometimes the final site of injection may 
occur between fascias or within connective tissue or fat. Absorption of the drug may be 
delayed, resulting in poor sedation. 
 
8.6 Safety 
 
Alpha-2 agonists have minimal toxicity and a remarkably wide safety margin (Kamibayashi 
et al., 2000). Alpha-2-compounds are excreted via the kidneys after elimination by 
biotransformation by the hepatic system (Salonen, 1989). 
Because alpha-2 agonists are mainly metabolized by the liver, it is implied that 
hepatic blood flow, and therefore cardiac output (reduced by alpha-2 agonists), might 
influence its pharmacokinetics and further, its clearance. However, in a study by Dutta et 
al., (2000) no clinically significant decrease in dexmedetomidine clearance was found in 
humans receiving the therapeutic dose range. In another report in human adults with severe 
hepatic failure, there was an increase of Vss and elimination T½ and a decrease in clearance 
(Cunningham et al., 1999).  
In a pharmacokinetics study on dexmedetomidine in humans severe renal 
impairment minimally affected pharmacological effects. The sedative effects were 
prolonged (probably because of lower plasma protein binding and therefore more effective 
and free molecules in the plasma) in patients with renal disease although the drug half-life 
was shorter (De Wolf et al., 2001). 
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8.7 Constant rate infusion 
 
A low dose medetomidine CRI may provide more constant levels of analgesia by 
maintaining constant plasma levels of alpha-2 agonists (Murrell and Hellebrekers, 2005). 
Intermittent administration of a drug may fail to provide its effects continuously. This 
problem can be overcome by administering analgesic by continuous infusion to maintain 
effective plasma level of analgesic (Flecknell, 2000). 
 In humans dexmedetomidine infusion at a dosage of 1 µg/kg  over 10 minutes 
followed by 0.2-0.7 µg/kg/h for less than 24 hours, is approved in many countries for use in 
the intensive care setting as a sedative in adults, initially intubated and mechanically 
ventilated patients, before, during, and after extubation 
(http://precedex.hospira.com/_docs/PrecedexPI.pdf). 
A study with dexmedetomidine CRI in dogs showed that at infusion levels of 0.5 
and 3.0 µg/kg/h (with loading dose of 0.5 or 3.0 µg/kg over 6 min, respectively) could be 
used to manage dogs undergoing surgery, where the provision of analgesia and limitation of 
stress is desirable (Pascoe et al., 2006). Dexmedetomidine is the active enantiomer in the 
racemate medetomidine and was found to produce approximately similar effects, when 
administered at half the dose, compared to medetomidine (Virtanen, 1989).  
A study using a high fentanyl bolus dose (15 µg/kg IV) during an 11-hour 
medetomidine CRI at 1.5 µg/kg/h showed that even with this small dose level of 
medetomidine there were marked hemodynamic changes. Decreased heart rate and cardiac 
index occurred in most dogs within 15-30 minutes of the beginning of the infusion without 
a loading dose. After one hour, all dogs had reduced heart rates. However, stroke volume 
index was not decreased, suggesting the change in cardiac index was related to lower heart 
rate. Profound cardiorespiratory effects were seen during co-administration of fentanyl 
bolus and medetomidine (Grimm et al., 2005). 
Although medetomidine will always be associated with some cardiovascular 
changes, these effects may be diminished by lowering the dose and using CRI to maintain 
adequate plasma concentrations (plasma levels slightly lower than those obtained with 2 
  
41
 
µg/kg IV). This alternative decreases the cardiovascular changes and controls the duration 
of sedation (Pypendop and Verstegen, 1998). 
Two recent studies with dexmedetomidine CRIs in dogs have demonstrated the 
usefulness of low-dose CRI administration in this species as a reliable and valuable adjunct 
during and after general anaesthesia (Lin et al., 2008; Uilenreef et al., 2008). Plasma 
concentrations were maintained, as well as sedative and anxiolytic effects, whilst 
hemodynamic effects were decreased and overall tissue perfusion remained adequate. 
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9.0 ALPHA-2 ANTAGONISTS 
 
A highly potent and selective antagonist of centrally and peripherally located alpha-2-
adrenoceptors, atipamezole, has been created for its use as a reversal agent for 
medetomidine (Virtanen, 1989). Atipamezole is able to antagonize the behavioural, 
cardiovascular, gastrointestinal, neurochemical, analgesic, and hypothermic effects of 
medetomidine (Virtanen, 1989; Savola, 1989; Vainio, 1990). 
In a study by Vainio (1990), the medetomidine-depressed heart rate was 
significantly increased by atipamezole, although not to the initial level. Simultaneously, the 
bradyarrhythmic features observed in ECG, were abolished (Vainio, 1990). 
The arousal time after IM atipamezole administration (dose approximately 5 times 
the dose of medetomidine) is more or less 5 minutes (Vähä-Vahe, 1990). Administration of 
the antagonist will also reverse analgesia produced by alpha-2 agonist (Short, 1992). 
Atipamezole can be given to reverse medetomidine in emergency situations. 
Atipamezole can reverse the cardiopulmonary effects of medetomidine in sick dogs, before 
any complications might be expected (Vainio, 1990). Usually, atipamezole is given to 
reverse the effects of medetomidine after non-painful diagnostic or therapeutic procedures, 
and is not usually given perioperatively. 
Complete reversal of the sedative and analgesic effects of medetomidine is achieved 
when atipamezole is given IM to dogs at 4-6 times the dose of medetomidine (Vähä-Vahe, 
1990). Atipamezole and anticholinergics can both cause dramatic heart rate increases. 
Concurrent use of these drugs should therefore be avoided. 
Recently, there has been increasing interest to find clinically useful alpha-2 
antagonists that specifically antagonise the peripheral cardiovascular effects whilst 
maintaining the centrally mediated sedative, analgesic and anxiolytic effects of 
dexmedetomidine and medetomidine (Enouri et al., 2008, Honkavaara et al., 2008). This 
may further increase the safety of these drugs, if clinically available selective peripheral 
antagonists become available. 
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10.0 RESEARCH HYPOTHESIS 
 
This literature review brings forward the hypotheses for the study. We first hypothesised 
that the cardiovascular effects of alpha-2 agonist medetomidine, as CRI, depend on the dose 
and that a dose level could be found with minimized cardiovascular changes. The second 
hypothesis is that this dose level of medetomidine CRI would represent a protocol for 
perioperative sedation and provision of analgesia, which could be demonstrated by 
measured adequate analgesic plasma concentrations. 
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Clinical Relevance 
This study investigated the dose-dependency of hemodynamic effects of IV 
medetomidine (MED) constant rate infusions (CRI) during isoflurane (ISO) anesthesia. 
Twenty-four healthy beagles randomly received one of six MED CRI regimens. A loading 
MED infusion was administered at 0.2, 0.5, 1.0, 1.7, 4.0 or 12.0 µg·kg-1 for 10 min, 
followed by a maintenance CRI providing identical dose amounts over 60 min. Heart rate 
(HR) and mean arterial blood pressure (MAP) were recorded, blood gases analyzed and 
cardiac index (CI) determined. Statistical analysis involved a repeated measures linear 
model. Baseline CI decreased dose-dependently as MED dose increased by: 14.9 (12.7), 
21.7 (17.9), 27.1 (13.2), 44.2 (9.7), 47.9 (8.1), and 61.2 (14.1) % respectively. The four 
lowest doses induced limited and transient changes in HR, MAP, and CI. Further 
investigation into potential perioperative uses of MED CRI is warranted. 
1. Introduction 
Medetomidine (MED) is a highly potent and selective alpha-2 agonist which has 
sedative, anxiolytic, muscle relaxant, and analgesic properties. It reduces requirements for 
other anesthetic agents and is widely used for sedation and pre-medication before general 
anesthesia in small animals1. It is supplied in a 50:50 racemic mixture of two optical 
enantiomers (dexmedetomidine and levomedetomidine), of which dexmedetomidine 
(DMED) is the active enantiomer2,3. Medetomidine has a very high affinity for alpha-2 
adrenoceptors where it acts as a full agonist and possesses a selectivity ratio of 1620/1 
(α2/α1) which is 5-10 times higher than for xylazine (α2/α1 ratio 160/1) or detomidine 
(260/1)2. 
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Medetomidine is licensed in North America to be administered intramuscularly 
(IM) or intravenously (IV). After IM administration, absorption of the drug is rapid as peak 
serum levels are reached within 30 min4. When given IV, the onset of action is rapid and 
the peripheral cardiovascular effects are more pronounced than by IM administration5. Low 
MED doses are adequate for perioperative use when given with other anesthetic/analgesic 
drugs, due to its significant sedative, analgesic, and anesthetic sparing effects6. 
In spite of the analgesic and perioperative stress response reducing effects7 MED 
has not been used to its full potential in veterinary medicine. Unfortunately, alpha-2-
adrenoceptor agonist administration, particularly IV, is associated with major side-effects 
on the cardiovascular system. These include a biphasic blood pressure response 
(hypertension, followed by normo- or hypotension) with reflex bradycardia and decreased 
cardiac index (CI), increased systemic vascular resistance (SVR) index and central venous 
pressure (CVP), and bradydysrhythmias8,9. Hence, these hemodynamic effects have 
popularized the use of low rate MED or DMED IV infusions in an attempt to improve the 
risk/benefit ratio. Several reports in the literature describe the clinical potential of this 
administration strategy10-13, however, to the authors’ knowledge, no previous study has 
quantified the dose-dependency of MED constant rate infusion (CRI) hemodynamic effects 
to determine a dose rate, which optimizes cardiovascular safety. 
It has been reported that the cardiovascular effects of MED following IV bolus 
administration in conscious dogs do not follow a clear dose-response relationship based on 
evaluation of, time-effect data5. It is possible that failure to reveal such a dose-response 
relationship could be related to inter-individual variation in the disposition 
pharmacokinetics of the drug. The aim of this study was to quantify the dose-dependency 
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of the cardiovascular/ hemodynamic effects when MED is administered as a CRI in 
isoflurane (ISO)-anesthetized dogs. To our knowledge, despite the recent quantification of 
the minimum alveolar concentration (MAC) sparing effect of DMED CRI11, the dose-
response effects of MED or DMED on the degree of cardiovascular depression are yet to be 
determined, and this information is necessary to establish an optimal dose rate. Two studies 
have been recently published investigating DMED CRIs in dogs. In one, a clinical study, 3 
doses (1, 2 and 3 µg·kg-1·h-1) of DMED resulted in acceptable mean arterial blood pressure 
(MAP) and adequate tissue perfusion13. A second, experimental study, using a single dose 
(25 µg·m-2·h-1) of DMED CRI compared cardiovascular and respiratory effects between 
propofol and isoflurane anesthetic groups12. They reported adequate oxygen delivery and a 
significant effect of general anesthetic on heart rate (HR), vasoconstriction and CI. In order 
to test the hypothesis that the intensity and duration of the hemodynamic changes 
associated with MED exposure vary as a function of dose rate, we administered MED at six 
different CRI dose rates. Furthermore, identification of a CRI dose rate associated with 
minimal hemodynamic effects that still maintains what has previously been proposed14 as 
an analgesic plasma concentration of MED would be of great interest. 
2. Materials and Methods 
2.1. Animals 
Clinically healthy purpose-bred laboratory beagles (n=24; 13 spayed females and 11 
castrated males) were used in this study. Dogs were between 1 and 3.5 years old and 
weighed between 8.6 and 16 kg. They were housed in groups of 6-7 dogs in large pens. 
Commercial dog food was given once daily and water was freely available. The care and 
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use of the dogs complied with Canadian Council for Animal Care15. The Animal care 
committee of the institution approved the study protocol (05-Rech-1298). All procedures 
were performed during the day, with two experiments completed during each study day. 
Dogs were brought to single cages the night before each study day, where water was given 
and food was withheld. Dogs were fed following full recovery from the experiment. All 
dogs were accustomed to handling and instrumentation. 
 
2.2. Treatments 
Each dog randomly received one of 6 treatments (6 groups, n=4 per group), in a 
prospective, controlled, blinded design. Medetomidine hydrochloride (Domitor; Orion 
Pharma, Espoo, Finland / Pfizer Animal Health, Kirkland, QC, Canada) was administered 
over 10 min as a manual loading infusion rate of 1.2, 3.0, 6.0, 10.2, 24.0 or 72.0 µg·kg-1·h-1, 
followed by a 60 min maintenance CRI at automated rates of 0.2, 0.5, 1.0, 1.7, 4.0 or 12.0 
µg·kg-1·h-1 respectively. Isoflurane (AErrane; Baxter Corp, Mississauga, ON, Canada) was 
administered during the whole duration of the experiment, including the time required for 
instrumentation and stabilization, a resting time where baseline values were recorded before 
MED administration, the 70 min-long exposure to MED combined with ISO, and again a 
60 min follow-up (ISO alone) after the end of MED CRI. 
 
2.3. Study procedure 
Each treatment was initiated by mask induction with ISO in oxygen. Dogs were 
intubated and general anesthesia was continued with the use of a Bain non-rebreathing 
system (Moduflex coaxial; Dispomed, QC, Canada) by maintaining the end-tidal ISO 
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concentration (ET-ISO) at a constant level of approximately 1.0 MAC (i.e. 1.3-1.4% in 
dogs16), and the ET-CO2 at 35-45 mmHg by controlled intermittent positive pressure 
ventilation (IPPV) (Hallowell EMC Model 2000 ventilator; Hallowell Engineering & 
Manufacturing Corp, Pittsfield, MA, USA). During the experiment, body temperature was 
monitored and stabilized at 37.0 Co with warm-water circulating heating mats (Micro-Temp 
II 747; Cincinnati Sub-zero Products Inc, OH, USA). Following initiation of IPPV, a 22 
SWG cannula (BD Insyte-WTM catheter; Becton Dickenson Infusion Therapy Systems Inc, 
UT, USA) was placed in the dorsal pedal artery of a pelvic limb, to monitor directly the 
systemic blood pressures, cardiac output (CO), and to collect arterial blood samples. Two 
20 SWG cannulas (BD Angiocath I.V. catheter; Becton Dickenson Infusion Therapy 
Systems Inc., UT, USA) were placed in each cephalic vein: one for MED infusion, and the 
other to allow administration of fluid (0.9% Sodium Chloride Injection USP; Baxter 
Corporation, Mississauga, ON, Canada) at a rate of 10 mL·kg-1·h-1, and lithium chloride 
(LiCl inj; LiDCO Ltd, London, UK). A 20 SWG cannula was placed in a jugular vein for 
venous blood sampling. Dogs were placed in lateral recumbency and arterial cannulas were 
connected to a transducer (Pressure Monitoring Kit with Truwave disposable Pressure 
Transducer; Edwards Lifesciences, Irvine, CA, USA) that was connected to a 
multiparametric vital signs monitor (Life window LW-6000 Multi-Parameter Vital Signs 
Monitor; Digicare Biomedical, FA, USA). The pressure transducer was adjusted to heart 
level. Heart rate, lead II electrocardiogram, direct systolic, diastolic, and mean systemic 
arterial pressures (SAP, DAP and MAP, respectively), pulse oximetry, capnography, ET-
ISO, and rectal temperature were recorded at 5-min intervals with the vital signs monitor 
from baseline until the end of the 130 min follow-up period. Systemic blood pressures and 
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HR were allowed to stabilize (three consecutive measurements with minimal variation: 
HR±5 bpm, MAP=60 mmHg±15 mmHg) before baseline values were recorded. 
Respiratory rate (RR) and tidal volume (TV) were also monitored and stabilized during the 
study. 
The lithium dilution method (LiDCO Ltd, London, UK) was used to measure CO 
and calculate CI, once at baseline and then every 10 min during the 130 min anesthesia. 
The LiDCO values were determined by use of a commercial LiDCO computer (LiDCO 
plus hemodynamic monitor HM 71-02, LiDCO Ltd, London, UK); measurements were 
performed according to manufacturer's instructions, and reports for small animals use17,18. 
Lithium chloride (5 µmol·kg-1) was administered for each CO measurement through the 
cannulated cephalic vein17. The SVR was calculated with the formula SVR=80 x (MAP-
CVP)/CO, where an average value of 4 mmHg was used for CVP. 
The MED loading doses were diluted with isotonic saline to a final 2 mL volume. 
Doses were hand-injected with 3 mL syringes over 10 min. All maintenance infusion doses 
were diluted with isotonic saline to a final 30 mL volume, and were administered through a 
cephalic venous cannula with an infusion pump (Harvard Apparatus 22, model 55-2222, 
MA, USA) over 60 min. 
Arterial and venous blood samples were taken from the pedal artery and jugular 
vein cannulas with syringes connected to 3-way stopcocks. The first 1 mL of blood diluted 
with the heparinized saline lock was discarded, the sample collected, and the cannula 
flushed with isotonic heparinized saline solution. Arterial and venous samples were drawn 
simultaneously for blood gas analysis at baseline (for control values) and at 15 and 45 min 
after starting the loading dose, using 1 mL heparinized (Hepalean, heparin sodium injection 
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USP 10000 UI·mL-1; Organon, Toronto, ON, Canada) syringes that were placed on ice 
immediately after sampling, and analyzed within 15-30 min (StatProfile M; Nova 
Biomedical, Waltham, MA, USA). Blood-gas values were corrected to body temperature. 
In addition to arterial and venous pH, oxygen and carbon dioxide tensions, plasma glucose, 
lactate and HCO3- concentrations were analyzed. Venous blood samples (5 mL) were 
collected into 10 mL dry vacuum tubes for drug concentration analysis before the 
beginning of the MED loading dose, and 5, 15, and 45 min after initiating the CRI. 
Additional venous samples were drawn at 30 and 60 min after the end of the maintenance 
CRI. Samples were allowed to clot at room temperature for 30 to 60 min, centrifuged for 15 
min at 1000×g at room temperature, and serum was harvested and stored at -80 Co pending 
analysis with liquid chromatography-electrospray ionization-tandem mass spectrometry 
(LC-ESI/MS/MS) techniques (LC-MS/MS system PESciex API 3+; Applied 
Biosystem/MDS Sciex, Concord, ON, Canada). The lower limit of detection for this method 
was 50 pg·mL-1, the coefficient of variation for the analysis was ≤ 11.1% and percentage 
bias ≤ 6%. 
 
2.4. Statistical analyses 
All numerical variables were analyzed by use of repeated-measures linear mixed-
effect models. All models were built with dose, time and the time × dose interaction as 
fixed-effect variables, and the animal nested into treatment as a random-effect variable. The 
variance-covariance matrix of the data was modeled according to a strategy described by 
Littell et al.19. Briefly, a mixed-effect model containing no interaction was estimated with a 
free covariance structure. The model was then re-estimated with more parsimonious 
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covariance matrices (e.g., variance components, compound symmetry, and first-order 
autoregressive), of which structures resembled that of the unstructured covariance matrix. 
The final covariance model was selected according to the value of the Schwarz Bayesian 
Criterion19. A number of a priori contrasts were performed to explore differences between 
pairs of means: a) differences between mean values at each time during the MED phase and 
the overall pretreatment mean for each treatment, and b) a comparison between mean 
values of each treatment at each time period. Critical level of significance for all 
comparisons was α = 0.05. Data are expressed as mean (SD) unless indicated otherwise. 
 
3. Results 
There was an even distribution of gender (2 males and 2 females per group) for all 
doses except with the 1.7 µg·kg-1·h-1 dose where there were 3 females and 1 male. Body 
weight did not significantly differ across dosing groups. 
 
3.1. Hemodynamic effects 
During MED administration, MAP and SVR initially increased and CI and HR 
decreased in a dose-dependent manner (Figure 1 and Table 1). From mean baseline values, 
MAP transiently increased for durations positively related to dose (Figure 1). Their 
maximal increase was 8.1 (22.9) (not statistically significant), 20.6 (16.5), 25.7 (39.3), 18.2 
(8.3), 35.6 (20.5), and 64.8 (17.7) % with increasing dose. The effect on SVR was 
undetected for the 0.2 µg·kg-1·h-1 dose, and significant only at 10 min for the 0.5 and 1.0 
µg·kg-1·h-1 doses (Table 1). The SVR maximally increased by 1.5 (23.8), 75.8 (19.7), 32.0 
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(27.4), 133.5 (35.4), 163.6 (67.8), and 328.5 (116.3) % with increasing dose. Compared 
with baseline value recorded before starting MED administration, CI decreased as MED 
dose increased for a maximal change of 14.9 (12.7), 21.7 (17.9), 27.1 (13.2), 44.2 (9.7), 
47.9 (8.1), and 61.2 (14.1) % respectively. The differences between certain group mean 
baseline values of CI were significant (p<0.0322, Table 1). More precisely, the effect of the 
three lowest MED infusion rates on CI was not significantly different from baseline 
(p>0.11). A significant decrease in HR was observed at all doses and returned to baseline in 
a dose-dependent fashion, except for the 4.0 µg·kg-1·h-1 dose, which returned to baseline 
before the 1.7 µg·kg-1·h-1 dose, and 10 min after finishing MED CRI (Table 1). HR 
maximally decreased by 15.1 (15.7), 30.8 (9.6), 17.5 (6.8), 35.9 (11.9), 44.8 (10.2), and 
53.3 (15.6) % with increasing dose. 
When the different doses were compared, the three lowest dose regimens showed small 
and short-lived changes in HR, CI, MAP and SVR which disappeared before the end of 
each maintenance CRI. Minimal changes were induced by the 0.2 µg·kg-1·h-1 dose. The 
maximal effect on SVR and HR (10 min after MED administration commenced; Table 1) 
with the 0.5 µg·kg-1·h-1 dose was greater than that of the 1.0 µg·kg-1·h-1 dose. The 1.7 μg·kg-
1·h-1 dose resulted in greater effects on hemodynamic variables, in magnitude and duration, 
than the three lowest doses. The exception was for MAP in the 1.0 µg·kg-1·h-1 dose group 
where a higher MAP was present from 60 minutes onwards. The two largest doses showed 
physiologically and statistically greater effects on each cardiovascular parameter and the 
duration of these effects was longer when compared to the three lowest doses (Figure 1). 
 
3.2. Medetomidine serum concentrations 
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Statistical comparison of the serum MED concentrations normalized to the unit dose 
(1.0 µg·kg-1·h-1) revealed significant effects of dose and time (p<0.0001 in both cases), as 
well as the time × dose interaction (p=0.0001). Visual inspection of Figure 2 shows higher 
dose-normalized concentration curves for the 0.2 and 0.5 µg·kg-1·h-1 groups, as compared to 
the four higher dosage groups. Of note, the dose-normalized serum MED concentrations 
during the maintenance CRI continued to increase in the 0.2 and 0.5 µg·kg-1·h-1 groups, but 
slightly decreased in the four higher dosage groups. The dose-normalized concentrations in 
the 0.2 µg·kg-1·h-1 group significantly differed with all other groups (p<0.0001 for all pair-
wise comparisons). The 0.5 µg·kg-1·h-1 group significantly differed from the 1.0, 1.7 and 
12.0 µg·kg-1·h-1 groups (p<0.0485). Differences between the four highest dosage groups 
were not statistically significant (p>0.12). 
 
3.3. Other effects 
The arterial pH of some dogs receiving the two highest MED infusions decreased 
below the physiologic limit (7.35), a difference that reached statistical significance in the 
12.0 µg·kg-1·h-1 group (Table 2). The values of the other measured respiratory, metabolic, 
and tissue perfusion variables (glucose, HCO3-, PaCO2, or lactate) stayed within a 
physiologically acceptable range during MED administration for both arterial and venous 
samples. Arterial oxygen tension (PaO2) was maintained in all dose regimens. However, 
venous oxygen tension decreased significantly with the three highest doses, with a tendency 
to be dose-dependent (Table 2). 
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4. Discussion 
The dose-dependency of MED effects on MAP, SVR, CI, and HR was documented 
quantitatively. The typical alpha-2 agonist-related increases in SVR and MAP associated 
with decreases in HR and CI were observed, and both the intensity and duration of these 
effects depended on CRI dose rate. Therefore, the results strongly suggest that a sigmoid 
concentration-response relationship exists. The hemodynamic effects were of a lesser 
intensity and shorter duration with the three lowest doses. They were greater and longer in 
duration with the middle dose (1.7 µg·kg-1·h-1) and most pronounced with both higher 
doses. The 0.2 µg·kg-1·h-1 group showed minimal effects in the intensity and duration of 
hemodynamic changes, and the 0.5 and 1.0 µg·kg-1·h-1 groups were similar. Of note, the 
intensity of effects was greater for the 0.5 µg·kg-1·h-1 group than 1.0 µg·kg-1·h-1 group for 
SVR and HR, but the magnitude of CI depression was as expected for each group. Also, the 
duration of these changes became longer with increasing dose. The maximal effects were 
seen shortly after loading dose administration with each dose regimen. These results with 
MED CRI in ISO-anesthetized dogs are comparable to those induced by a bolus IV 
administration of MED in conscious dogs5 but, by comparison, our dogs anesthetized with 
ISO had lower baseline values for MAP, HR, and CI. As a result, the initial hypertensive 
effects of MED administration were more evident in ISO-anesthetized dogs, allowing better 
differentiation of their dose-response relationships. No hypotension was subsequently 
observed. The maximal increase in SVR recorded for our 4.0 µg·kg-1·h-1 and 12.0 µg·kg-1·h-
1 groups were 163.6% and 328.5%, respectively, which is comparable to values recorded in 
conscious dogs dosed with 5 and 10 µg·kg-1 MED5. After the administration of 1 µg·kg-1 
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MED, the increase in SVR was approximately 210% in conscious dogs, which was 
markedly higher than that observed in the 1.0 µg·kg-1·h-1 group, a difference that may be 
attributed to the use of bolus administration in conscious dogs (given IV over 5 sec; B. 
Pypendop, personal communication, 2009) instead of an infusion over 10 min. The 
magnitude of the decreases in HR and CI documented in our 1.7 µg·kg-1·h-1 group was 
comparable with previous results reported with 1.5 µg·kg-1·h-1 MED where HR decreased 
by 41.7% and CI decreased by 41.2%10. Data in this study are also consistent with 
previously reported results with corresponding doses of DMED12,20. 
The cardiovascular effects of DMED have been suggested to depend on the initial status 
of blood vessel tone12. It has also been suggested that the central sympatholytic effects may 
predominate at small doses, which stimulate the alpha-2A adrenoceptor subtype 
preferentially and produce the characteristic sedation and analgesia, while the peripheral 
effects predominate when higher doses or rapidly injected loading doses are administered 
due to stimulation of the alpha-2B adrenoceptor subtype21. This has been recently confirmed 
by the IV combination of a peripheral alpha-2 adrenoceptor antagonist (L-659’066) with a 
dose (10 µg·kg-1) of DMED which attenuated the cardiovascular effects typically associated 
with DMED alone while still producing the expected level of sedation22. In spite of this, our 
study demonstrated a dose-dependency in intensity and duration of cardiovascular effects. 
The persistent increase in MAP for the 1.0 µg·kg-1·h-1 dose (Figure 1) was related to the 
individual response of two out of four tested dogs (note the high variability [SD] of results 
after MED administration for this dose in Table 1), which did not show such a response in 
subsequent evaluations (data not shown) when receiving the same MED dose under ISO-
anesthesia. Technical difficulties with the arterial line, or an insufficient level of anesthesia 
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could explain the result for these two dogs. Of note, at low doses, the hemodynamic effects 
were small and transient, even disappearing before the end of CRI administration period. 
The peripheral vasoconstriction resulting from an alpha-2B-induced increase in SVR was 
very limited in intensity and duration at the three lowest dosages (0.2, 0.5 and 1.0 µg·kg-1·h-
1). This pharmacological action governs the increase in MAP and contributes to the 
bradycardic response, leading to reduced CI. Particularly evident at these low doses, HR 
was reduced for a longer time in comparison to other hemodynamic parameters. This 
persistent bradycardia has also been reported previously even at low serum concentrations 
(< 3.9 ng·mL-1) in dogs3 and it has been theorized that this could be related to stimulation of 
central alpha-2A adrenoceptors23. Taken together, these results suggest that low doses of 
MED CRI during ISO anesthesia in dogs are associated with minimal hemodynamic 
changes. Whether these low doses also induce efficacious analgesia, muscle relaxation, and 
sedation remains to be determined.  
The infusion rates (0.2, 1.0, 4.0 and 12.0 µg·kg-1·h-1) of MED for this study were 
extrapolated from DMED infusion rates and published pharmacokinetic and 
pharmacodynamic data3,4,11,24. Two intermediate doses (0.5 and 1.7 µg·kg-1·h-1) were added 
to accurately quantify the dose-dependent nature of the hemodynamic effects. The aim of 
the highest dose level was to provide a positive control, producing clinically significant 
cardiovascular effects. Within each group, the total doses of MED given during the loading 
and maintenance CRI periods were equal, and it appears clear that the loading doses were 
responsible for the dose-dependent effects on cardiovascular function that were noted. In 
the present study, in contrast to the conclusions derived from data in conscious dogs5, 
increasing the dose not only prolonged the duration of drug effects, but also influenced the 
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magnitude of the cardiovascular effects in ISO-anesthetized dogs. While the four higher 
CRI rate (12.0, 4.0, 1.7 and 1.0 µg·kg-1·h-1) groups demonstrated homogenous 
pharmacokinetics, the two lowest dosage (0.5 and 0.2 µg·kg-1·h-1) groups demonstrated a 
different pharmacokinetic pattern. Specifically, the lower the rate below 1.0 µg·kg-1·h-1, the 
greater was the dose-normalized plasma concentration. This is further evidenced by the 
difference in decay slopes upon completion of the initial loading dose between the four 
highest and the two lowest dosage groups, with a plateau never being achieved during CRI 
administration in the lowest dosage groups. The difference in dose-normalized MED 
concentrations strongly suggests that MED systemic clearance increased with dose and 
reached a plateau. MED is mainly (80-90%) metabolized by hepatic hydroxylation 
followed by glucuronidation in dogs involving several biotransformation pathways14. 
While an evaluation of the metabolite kinetics of MED was beyond the scope of this 
study, recent publications provide indirect support for this hypothesis. The phase II 
glucuronidation of MED is actually accomplished by different UDP-
glucuronosyltransferases with different affinity, regio-and stereo-selectivity in human and 
canine liver microsomes leading to N-glucuronidation of levomedetomidine (LMED) and 
DMED with different kinetics25. In addition, an O-glucuronidation pathway has been 
reported for MED14. Hence it is conceivable that at dose rates below 1.0 µg·kg-1·h-1, MED 
is metabolized by one pathway only, while the activity of other metabolic pathways 
becomes significant at increased dosages. Alternatively, DMED may require chiral 
conversion to LMED in order to be N-glucuronidated at low doses. But with increasing 
racemic dose, DMED may be involved in direct N-glucuronidation, which would hasten the 
elimination of MED. This is supported by an earlier report stating that clearance of LMED 
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is more rapid than DMED or racemic MED in dogs3. Another hypothesis is grounded on 
the phenotypic polymorphism of the cytochrome P450 (CYP)-catalyzed phase I 
hydroxylation of MED, a feature reported in rabbits26. If such polymorphism does exist in 
dogs, it would induce more rapid biotransformation of MED and different systemic 
exposure to the drug.  
In contrast to a report from Dutta et al.24 in human beings, we did not observe the 
pharmacodynamic alteration of MED clearance with increasing dose. In the above-cited 
study, the authors showed with pharmacokinetic / pharmacodynamic modeling that cardiac 
output and hepatic blood flow depression induced by MED decreased its own hepatic 
clearance. This could be explained by the major species differences in MED metabolism27 
and the possible interference of ISO-anesthesia on MED-induced hemodynamic effects. 
A metabolic acidosis has been reported in earlier studies with MED and DMED13,28, 
and was sporadically found at the highest dosage rates used in the current study. Since 
lactate-free fluids were administered in our study and in the study from Uilenreef et al.13, 
the possibility of hyperchloremic acidosis was verified and changes in arterial or venous 
concentrations of chloride were not demonstrated (data not shown). Furthermore, in our 
study, this effect was apparent only with higher doses, which also argues against fluid 
induced acidosis. In this study, blood gas measurements did not extend beyond MED 
administration. However, based on previous reports, the magnitude of this acidosis is not 
clinically relevant28. This study demonstrated a dose-dependent effect on pH which has not 
been shown in earlier studies. This indicates a further advantage of decreasing the MED 
CRI dose below the level of potential metabolic acidosis induction. 
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Arterial oxygen tension (PaO2) during 100 % oxygen administration was high, as 
expected, at all dose regimens. Venous oxygen tension (PvO2) decreased significantly 
during the administration period of the three highest doses and this decrease had a dose-
dependent tendency even though there were no statistically significant differences between 
these doses. This implies increased oxygen extraction during higher MED doses, which is 
consistent with a prior report with DMED12. The underlying cause may be due to a 
decreased CI and peripheral blood flow. Our study was a minimally invasive study and the 
dogs were instrumented with peripheral cannulas only. Thus, central mixed venous blood 
samples were not available and oxygen consumption and extraction could not have been 
calculated accurately. However, based on the results available, the extraction of oxygen 
appears to increase dose-dependently, which has not been reported previously with MED or 
DMED. Even though the oxygen balance would remain positive with increasing doses 
while its extraction is increased12, these results indicate a further advantage of the use of 
low dose MED CRI when compared with higher doses. 
Arterial and venous values of pH, PCO2, HCO3-, glucose, and lactate remained within 
clinically acceptable ranges during each dose of MED CRI, and were consistent with 
previous findings11,12. Venous values of pH, PvCO2, HCO3-, glucose, and lactate showed 
comparable results to arterial values with normal arterio-venous differences and thus only 
arterial values were reported here. However, plasma glucose levels are expected to increase 
with MED administration due to its ability to inhibit insulin release from the pancreas29. 
This was not demonstrated in our study, probably because samples were not taken beyond 
the end of infusion. Medetomidine has been found to produce slow (i.e. peaks in 2 to 4 
hours post-administration) and non-significant changes in plasma glucose 
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concentrations30,31. Arterial lactate concentrations remained within normal physiologic 
range (below 2.5 mmol·L-1) with all dose regimens. This was consistent with findings from 
recent reports11,13 with DMED during anesthesia, implying that the overall tissue perfusion 
was maintained during our study. Again, in our study, lactate measurement did not continue 
after MED CRI, and thus potential lactate retention during CRI may have occurred. Based 
on a previous study, some lactate retention may occur when increasing the dose of DMED 
CRI to 3 µg·kg-1·h-1 13 but it was not demonstrated with lower doses. Thus, it may be 
speculated that lactate retention should not occur with low doses of MED CRI either. 
With regard to the multitude of possible clinical uses of low dose DMED CRI in human 
patients21,32 and the increasing volume of promising studies being published, the full 
application of these drugs may soon be realized in the veterinary domain. Potential 
indications for MED or DMED CRI in veterinary patients may include use as an adjunct to 
balanced anesthesia to enhance perioperative hemodynamic stability, as an adjunct to 
perioperative multimodal analgesia, and as a sedative-analgesic for use in intensive care 
units. 
 
5. Conclusion 
 In conclusion, these results demonstrate the dose-dependency of the hemodynamic 
effects of MED CRI when used as an anesthetic adjunct to ISO-anesthetized dogs. The low 
dose MED CRI rates (0.2-1.7 µg·kg-1·h-1) induced limited and transient hemodynamic 
effects and showed fewer changes in pH and oxygen extraction when compared to higher 
doses. Thus, low dose MED CRI rates may prove clinically useful in the perioperative 
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management of canine patients. Further studies are warranted to demonstrate and quantify 
the efficacy of such CRI doses as analgesic and anesthetic adjuncts. This is particularly 
important as the correlation between the pharmacodynamic effects and serum MED 
concentrations may not be linear at all dose rates as suggested by the data presented here. 
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Tables 
 
Table 1 – Hemodynamic parameters [mean (SD)] measured at baseline (-5 minutes), and 
medetomidine constant rate infusion effect’s characteristics during isoflurane anesthesia. 
 
 
Parameter (units) 
Dose 
(µg·kg-1·h-1)
Baseline 
value at -
5 minutes 
Duration of 
statistically 
significant 
effect (min) 
Peak effect value 
Zenith Nadir 
MAP (mmHg) 
0.2 59 (8) Not present Not presenta,c  
0.5 62 (7) 10 70 (10)a  
1.0 59 (2) 10 74 (23)b  
1.7 73 (20) 10 85 (6)c  
4.0 69 (14) 70 94 (14)a  
12.0 70 (10) 85 116 (12)a,b,c  
SVR 
(Dynes·second·cm-5) 
0.2 4782 (1203) Not present Not presenta,b,c  
0.5 5222 (1407) 10 9178 (1031)a,d  
1.0 4062 (1246) 10 5357 (890)d,e,f  
1.7 3797 (336) 20 8867 (1344)b,e  
4.0 3486 (295) 70 9190 (2365)c,f  
12.0 3780 (493) 130 16197 (4396)a,b,c,e,f  
CI (L·min-1·m-2) 
0.2 2.3 (0.4)a,b Not present  Not presenta 
0.5 2.2 (0.5)c,d,e Not present  Not presentb
1.0 2.4 (0.4) Not present  Not presentc
1.7 3.3 (0.7)a,c 70  1.9 (0.3)
4.0 3.3 (0.7)b,d 80  1.7 (0.3) 
12.0 3.1 (0.7)e 130  1.2 (0.4)a,b,c
HR (Beats·min-1) 
0.2 96 (22) 5  82 (15)a,b,c 
0.5 85 (9)a 40  59 (8)a,d
1.0 93 (7) 60  77 (6)d,e,f
1.7 115 (26) 130  74 (14) 
4.0 96 (13) 70  55 (11)b,e
12.0 109 (20)a 130  55 (16)c,f
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Table 2 – Parameters [mean (SD)] measured in arterial and peripheral venous samples prior to (-10 
minutes) and during medetomidine constant rate infusion with isoflurane anesthesia in dogs. 
   Medetomidine constant rate infusion with 
isoflurane anesthesia  Dose Baseline 
Blood parameter (µg·kg-1·h-1) -10 minutes 25 minutes 55 minutes 
pH (arterial) 0.2 7.38 (0.04) 7.39 (0.04)a 7.37 (0.04)a
 0.5 7.44 (0.05)a,b 7.44 (0.06)b,c,d 7.42 (0.06)b,c
 1.0 7.39 (0.02) 7.39 (0.02)e 7.39 (0.03)d
 1.7 7.37 (0.03)a 7.36 (0.03)b 7.37 (0.03)b
 4.0 7.40 (0.03) 7.37 (0.05)*,c 7.38 (0.03)*,e
 12.0 7.37 (0.07)b 7.33(0.04)*,a,d,e 7.32 (0.04)*,a,c,d,e
PaO2 (arterial) 0.2 501.0 (39.8) 502.2 (59.6) 512.3 (42.7) 
MmHg 0.5 491.3 (73.2) 514.1 (51.6) 490.4 (39.0) 
 1.0 554.7 (4.7) 546.4 (26.4) 550.5 (13.6) 
 1.7 448.8 (220.3)   445.8 (218.9) 535.9 (38.8) 
 4.0 519.6 (33.6) 547.4 (22.6) 551.7 (26.5) 
 12.0 555.1 (26.0) 538.4 (54.0) 536.0 (56.9) 
     
PvO2 (peripheral jugular vein) 0.2 155.4 (66.6) 162.2 (94.0) 201.8 (95.3)a
MmHg 0.5 136.0 (51.0) 93.5 (19.7) 130.1 (45.7) 
 1.0 192.5 (94.4) 168.2 (119.5) 157.3 (115.6) 
 1.7 210.6 (139.6) 103.3 (18.2)* 104.7 (42.0)* 
 4.0 216.7 (56.7) 87.4 (20.4)* 89.5 (18.7)* 
 12.0 198 (110.4) 67.1 (12.5)* 78.2 (9.9)*,a
     
PaCO2 (arterial) 0.2 39.0 (5.1) 40.8 (4.8) 46.4 (3.4)*,a
MmHg 0.5 39.7 (5.8) 34.5 (1.1)*,a 33.9 (4.2)*,a,b,c,d 
 1.0 38.3 (5.4) 39.0 (6.4)b 41.5 (6.0)c
 1.7 40.5 (1.8) 45.8 (2.6)*,a,b,c 42.8 (3.2)b,e
 4.0 35.6 (6.2)a 40.7 (4.1)* 42.8 (3.1)*,d
 12.0 42.5 (4.2)a 45.7 (4.7)c 45.7 (6.9)e
     
Glucose (arterial) 0.2 5.95 (1.24) 6.18 (0.56) 5.93 (0.51) 
mmol·L-1 0.5 5.73 (0.91) 6.10 (0.71) 5.67 (0.55) 
 1.0 5.43 (1.17) 5.45 (1.10) 5.38 (0.43) 
 1.7 5.43 (1.35) 6.33 (0.55) 6.57 (0.47)* 
 4.0 5.88 (0.68) 6.33 (0.54) 5.98 (0.77) 
 12.0 5.87 (0.95) 5.53 (1.08) 5.48 (0.60) 
     
Lactate (arterial) 0.2 N/A N/A N/A
mmol·L-1 0.5 N/A N/A N/A
 1.0 1.55 (0.62) 1.58 (0.69) 1.33 (0.60) 
 1.7 1.33 (0.19) 1.08 (0.25) 1.05 (0.33) 
 4.0 1.30 (0.69) 1.20 (0.41) 0.85 (0.42)* 
 12.0 1.63 (0.61) 1.47 (0.67)* 1.47 (0.93)* 
     
HCO3- (arterial) 0.2 25.1 (3.4) 25.6 (4.3) 28.8 (4.5)* 
mmol·L-1 0.5 27.0 (2.7)a 23.6 (3.4)* 22.2 (0.6)* 
 1.0 23.2 (2.3) 23.4 (3.1) 25.1 (2.8) 
 1.7 23.7 (1.6) 26.0 (3.4) 25.0 (3.7) 
 4.0 22.6 (3.1)a 23.5 (2.8) 25.4 (3.2)* 
 12.0 24.7 (2.3) 24.2 (0.6) 23.7 (1.5) 
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Legends 
 
Figure 1 – Changes in mean systemic arterial blood pressure (MAP), systemic vascular 
resistance (SVR), cardiac index (CI), and heart rate (HR) during administration of 
isoflurane and six doses of medetomidine (MED) CRI, shown as percentages change(SD) 
from each group mean baseline values. Time 0 (min) = beginning of MED loading dose 
administration. Time 10 (min) = beginning of MED CRI. Time 70 (min) = MED CRI 
administration completed.  
 
Figure 2 – Mean serum medetomidine (MED) concentrations (with 95% confidence 
intervals) for the six different groups, normalized to 1.0 µg·kg-1·h-1 infusion rate. Blood 
sampling were taken at Time 15, 25, 55, 100, and 140 min. Time 0 (min) = beginning of 
MED loading dose administration. Time 10 (min) = beginning of MED CRI. Time 70 (min) 
= MED CRI administration completed. A semi-logarithmic scale was used for presenting 
the data and artefactually all concentrations started from zero as baseline value. 
 
Table 1 – Hemodynamic parameters [mean (SD)] measured at baseline (-5 minutes) and 
medetomidine constant rate infusion effect’s characteristics during isoflurane anesthesia. 
MAP, mean systemic arterial blood pressure; SVR, systemic vascular resistance (see text 
for calculation); CI, cardiac index; HR, heart rate. Values of a given hemodynamic 
parameters with same superscript letter significantly differ (p < 0.05). 
 
Table 2 – Parameters [mean (SD)] measured in arterial and peripheral venous samples 
prior to   (-10 minutes) and during medetomidine constant rate infusion with isoflurane 
anesthesia in dogs. 
* Within a row, mean value differs from baseline (p < 0.05). Within a column, values with 
same superscript letter significantly differ; differences between doses (p < 0.05). 
N/A = value not available. 
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Figures 
 
Figure 1 – Changes in mean systemic arterial blood pressure (MAP), systemic vascular 
resistance (SVR), cardiac index (CI), and heart rate (HR) during administration of 
isoflurane and six doses of medetomidine (MED) CRI, shown as percentages change(SD) 
from each group mean baseline values. Time 0 (min) = beginning of MED loading dose 
administration. Time 10 (min) = beginning of MED CRI. Time 70 (min) = MED CRI 
administration completed.  
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Figure 2 – Mean serum medetomidine (MED) concentrations (with 95% confidence 
intervals) for the six different groups, normalized to 1.0 µg·kg-1·h-1 infusion rate. Blood 
sampling were taken at Time 15, 25, 55, 100, and 140 min. Time 0 (min) = beginning of 
MED loading dose administration. Time 10 (min) = beginning of MED CRI. Time 70 (min) 
= MED CRI administration completed. A semi-logarithmic scale was used for presenting 
the data and artefactually all concentrations started from zero as baseline value. 
 
 
 THIRD CHAPTER – DISCUSSION AND 
CONCLUSION 
 
Discussion 
 
The dose-dependency of the hemodynamic effects of MED CRI on MAP, SVR, CI, and HR 
was quantified. The typical changes after alpha-2 agonist administration were observed; 
increases in SVR and MAP associated with decreases in HR and CI were observed. These 
effects were small to moderate in intensity and short in duration with the three smallest 
doses. They were greater and longer in duration with the middle dose (1.7 µg·kg-1·h-1) and 
most pronounced with both higher doses. The 0.2 µg·kg-1·h-1 group showed minimal effects 
in the intensity and duration of hemodynamic changes, and the 0.5 and 1.0 µg·kg-1·h-1 
groups were similar. Of note, the intensity of effects was greater for the 0.5 µg·kg-1·h-1 
group than 1.0 µg·kg-1·h-1 group for SVR and HR, but the magnitude of CI depression was 
as expected for each group. Also, the duration of these changes became longer by 
increasing the dose. The maximal effects were observed shortly following loading dose 
administration with each dose regimen.  
These results with MED CRI in ISO-anesthetized dogs are comparable to those 
induced by a bolus IV administration of MED in conscious dogs (Pypendop and Verstegen, 
1998) but, by comparison, the presence of ISO had a significant effect on baseline values: 
MAP (approximately 60-75 mmHg in our study, versus 120-140 mmHg in conscious dogs), 
HR (90-110 beats·min-1 versus 120-130 beats·min-1), and CI (2-3.5 L·min-1·m-2 versus 5-7 
L·min-1·m-2). As a result, the initial hypertensive effect of MED administration was more 
evident in ISO-anesthetized dogs, allowing better differentiation of their dose-response 
relationships. No hypotension was subsequently observed. The maximal increase in SVR 
recorded for our 4.0 µg·kg-1·h-1 and 12.0 µg·kg-1·h-1 groups were 163.6% and 328.5%, 
respectively, which is comparable to values recorded in conscious dogs dosed with 5 and 
10 µg·kg-1 MED (Pypendop and Verstegen, 1998). After the administration of 1 µg·kg-1 
MED, the increase in SVR was approximately 210% in conscious dogs, which was 
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markedly higher than that observed in the 1.0 µg·kg-1·h-1 group, a difference that may be 
attributed to the use of bolus administration in conscious dogs (given IV over 5 sec; B. 
Pypendop, personal communication, 2009) instead of an infusion over 10 min. The loading 
dose infusion could partially explain the apparent discrepancy observed between the 0.5 
µg·kg-1·h-1 and 1.0 µg·kg-1·h-1 groups, because the loading dose administration was not 
automated. It is possible that, in some dog(s), the administration rate was faster in the 0.5 
µg·kg-1·h-1 group than 1.0 µg·kg-1·h-1 group. The magnitude of change in group 1.7 µg·kg-
1·h-1 in HR was comparable with results associated to a CRI of 1.5 µg·kg-1·h-1 MED leading 
to decrease in HR (-41.7%) and CI (-41.2%) (Grimm et al., 2005). Data in this study are 
consistent with previously reported results with corresponding doses of DMED (Flacke et 
al., 1993; Lin et al., 2008). 
The cardiovascular effects of DMED have been suggested to depend on the initial 
status of the blood vessel tone (Lin et al., 2008). It was additionally suggested that the 
central sympatholytic effects may predominate at small doses, which stimulate the alpha-2A 
adrenergic receptor subtype (source of sedation and analgesia), while at higher or rapidly 
injected loading doses, greater peripheral effects arise, which result from stimulation of the 
alpha-2B adrenoceptors (Aantaa and Jalonen, 2006). This has been recently confirmed by 
the IV combination of a peripheral alpha-2 adrenoceptor antagonist (L-659’066, 250 µg·kg-
1) with a dose (10 µg·kg-1) of DMED, attenuating the cardiovascular effect apparent with 
DMED alone, but leading to similar sedation (Honkavaara et al., 2008). In our study, there 
was an initial increase in MAP followed by maintained blood pressures with the 1.0, µg·kg-
1·h-1 dose, while with the 1.7, µg·kg-1·h-1 dose there was a more typical biphasic effect with 
initial increase followed by decrease of MAP. The baseline values of HR, CI, and MAP 
with dose 1.7 were slightly different from the smaller doses. This initial difference may 
indicate a disparity in blood vessel tone in the individuals and may help to explain, at least 
in part, the difference of effect demonstrated on MAP between doses 1.0 and 1.7.  
In addition, an important factor influencing our results was the variability in the rate 
of the loading dose injection because it was hand-injected instead of using a constant rate 
infusion pump. This may increase the interindividual variance to some extent. In spite of 
these influencing factors, this study demonstrated a dose-dependency in intensity and 
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duration of cardiovascular effects. The persistent increase in MAP for the 1.0 µg·kg-1·h-1 
dose was related to the individual response of two out of four tested dogs, which did not 
show such response in subsequent evaluations (data not reported) when receiving the same 
MED dose under ISO-anesthesia. Technical difficulties with the arterial line or an 
insufficient level of anesthesia may explain the result for these two dogs. 
It is interesting to note that at lowest doses the hemodynamic effects were small and 
transient, disappearing before the end of CRI administration. The peripheral 
vasoconstriction resulting from alpha-2B-induced increase in SVR was very limited in 
intensity and duration at the three lowest dosages (0.2, 0.5, and 1.0 µg·kg-1·h-1). This 
pharmacological action governs the increase in MAP and contributes to the bradycardic 
response, leading to reduced CI. Particularly evident at these low doses, HR was reduced 
for a longer time in comparison to other hemodynamic criteria, as demonstrated in an 
earlier report, where HR decrease also persisted at low serum concentrations (< 3.9 ng·mL-
1) in dogs (Kuusela et al., 2000). This could be related to bradycardic and potentially 
hypotensive stimulation of central alpha-2A adrenoceptors (Maze and Fujinaga, 2000). This 
suggests that low doses of MED CRI may be used during ISO anesthesia in dogs with 
minimal hemodynamic changes. The question remaining is whether such low doses of 
MED CRI could induce efficacious analgesia, muscle relaxation, and sedation. 
Four infusion rates (0.2, 1.0, 4.0, and 12 μg kg-1 h-1) of MED for this study were 
extrapolated from DMED infusion rates and published pharmacokinetic and 
pharmacodynamic data (Salonen, 1989; Dutta et al., 2000; Kuusela et al., 2000; Pascoe et 
al., 2006) and two intermediate doses (0.5 and 1.7 μg kg-1 h-1) were added to accurately 
quantify the dose-dependency of hemodynamic effects. The aim of the highest dose level 
was to provide a positive control, producing clinically significant cardiovascular effects. 
Loading doses were given at a numeric dose identical to the following infusion rate. 
Obviously, these loading doses were responsible for the dose-dependency on intensity, and 
that in contrast to the conclusions derived from conscious dog data (Pypendop and 
Verstegen, 1998), as increasing the dose above 5 µg·kg-1 not only prolongs drug effects, but 
also influences cardiovascular function in ISO-anesthetized dogs. The higher serum 
concentrations of MED immediately after loading dose administration correlated with the 
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more pronounced effects on hemodynamic data. Thus, lowering the loading dose may be 
indicated when intending to further decrease hemodynamic effects while maintaining 
analgesia and anxiolysis.  
A difference in pharmacokinetics between higher and lower CRI dose rates was 
apparent in this study: Whilst the four higher CRI rates (12.0, 4.0, 1.7 and 1.0 µg·kg-1·h-1) 
demonstrated homogenous pharmacokinetics, the two lowest rates (0.5 and 0.2 µg·kg-1·h-1) 
groups presented a different pharmacokinetic pattern. One hypothesis is that, the lower the 
rate below 1.0 µg·kg-1·h-1, the greater could be the degree of accumulation of the drug in the 
central compartment. This might explain the apparent absence of a statistically significant 
difference in the MED serum concentration observed for the four lower dosage groups. It 
has been previously reported that MED in the circulation is present in its inactive protein 
bound form (Salonen, 1989). Being a weak organic base, MED at high dose (80 µg·kg-1) 
presented a low free fraction (fu) estimated at 15% in dogs, cats and rats, binding of the 
drug to α-proteins (globulins, lipoproteins, glycoproteins) is suspected. It may be suggested 
from the results of this study that fu may be lower at doses below 1.0 µg·kg-1·h-1. This could 
explain the apparent higher accumulation at low doses and the associated lower fu leading 
to fewer pharmacodynamic effects. This phenomenon requires further pharmacokinetic / 
pharmacodynamic exploration.  
Another possible hypothesis to explain the differences in pharmacokinetics is that, 
the lower the rate below 1.0 µg·kg-1·h-1, the greater appears to be the dose-normalized 
plasma concentration. This is further evidenced with the difference in decay slopes upon 
completion of the initial, fast-rate infusion between the four highest and the two lowest 
dosage groups, resulting in an absence of plateau during CRI administration for the latter. 
This difference in dose-normalized MED concentrations strongly suggests that MED 
systemic clearance increased with dose and reached a plateau. Medetomidine is mainly (80-
90%) metabolized by hepatic hydroxylation followed by glucuronidation in dogs involving 
several biotransformation pathways (Salonen, 1992). This phase I reaction proceeds with a 
rate sufficient for the rapid removal of the drugs from the animal body and is mainly 
regulated by the hepatic blood flow. 
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The difference in clearance between doses is suggestive that at a dose rate below 1.0 
µg·kg-1·h-1, MED is metabolized through a high-affinity, limited-capacity pathway, and 
with higher dose rates, the drug is going through a second pathway presenting lower-
affinity and bigger capacity. The study of metabolite kinetics of MED was outside the 
scope of this study, but some recent publications provide indirect support for this 
hypothesis. The phase II glucuronidation of MED with glucuronic acid is accomplished by 
different UDP-glucuronosyltransferases with different affinity, regio-and stereo-selectivity 
in human and canine liver microsomes leading to N-glucuronidation of levomedetomidine 
(LMED) and DMED with different kinetics (Kaivosaari et al., 2008). In addition, an O-
glucuronidation pathway has been reported for MED (Salonen, 1992). Hence it is 
conceivable that at dose rates below 1.0 µg·kg-1·h-1, MED is metabolized by one pathway 
only, and the activity of other metabolic pathways becomes significant at increased 
dosages. Alternatively, DMED may require chiral conversion to LMED in order to be N-
glucuronidated at low doses. But with increasing racemic dose, DMED may be involved in 
direct N-glucuronidation, which would fasten the elimination of MED. This is supported by 
an earlier report about clearance of LMED being more rapid than DMED or racemic MED 
in dogs (Kuusela et al., 2000). In addition, LMED has been shown to interfere with the 
metabolism of other anesthetic drugs in the liver, such as slowing ketamine metabolism 
(Kharasch et al., 1992). Another hypothesis is grounded on the phenotypic polymorphism 
of the cytochrome P450 (CYP)-catalyzed phase I hydroxylation of MED, that affects the 
biotransformation rate of MED, a feature reported in rabbits (Avsaroglu et al., 2008). If 
such polymorphism would exist in dogs, it would induce biotransformation rate of MED 
and different systemic exposure to the drug. In contrast with a report from Dutta et al. 
(2000) in humans, we did not record the pharmacodynamic alteration of MED clearance 
with increasing dose. In the above-cited study, the authors shown with pharmacokinetic / 
pharmacodynamic modeling that cardiac output and hepatic blood flow depression induced 
by MED decreased its own hepatic clearance. This could be explained by the major species 
differences in MED metabolism (Kaivosaari et al., 2002) and the possible interference of 
ISO-anesthesia on MED-induced hemodynamic effects. 
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There was a physiologically significant decrease in pH during MED administration 
with the two largest doses only. A metabolic acidosis has been reported in earlier studies 
with MED and DMED (Kuusela et al., 2001; Uilenreef et al., 2008). Since lactate-free 
fluids were administered in this study and in the study reported by Uilenreef et al. (2008) 
the possibility of hyperchloremic acidosis was verified and changes in arterial or venous 
concentrations of chloride were not demonstrated (data not shown). Furthermore, in our 
study this effect was apparent only with higher doses, which also argues against fluid 
induced acidosis. In this study, blood gas measurements did not extend beyond MED 
administration. However, based on a previous report, the magnitude of this acidosis is not 
clinically relevant (Kuusela et al., 2001). This study demonstrated the dose-dependent 
effect on pH, which has not been shown in earlier studies. This indicates a further 
advantage of decreasing the MED CRI dose below the level of potential metabolic acidosis 
induction. 
Arterial oxygen tensions (paO2) during 100 % oxygen administration were 
expectedly high during each dose regimen. Venous oxygen tensions (pvO2) decreased 
significantly during administration of the three highest doses and this decrease had a dose-
dependent tendency even though there were no statistically significant differences between 
these doses. This implies increased oxygen extraction during higher MED doses, which is 
consistent with a prior report with DMED (Lin et al., 2008). The underlying cause may be 
due to decreased CI and peripheral blood flow. This study was minimally invasive and dogs 
were instrumented only with peripheral catheters. Thus, central mixed venous blood 
samples were not obtainable and oxygen consumption and extraction could not have been 
calculated accurately. However, based on the results of peripheral oxygen tensions 
available, the extraction of oxygen appears to increase dose-dependently, which has not 
been reported previously with MED or DMED. Even though the oxygen balance would 
remain positive with increasing doses while its extraction is increased (Lin et al., 2008), 
these results indicate a further advantage of the use of low dose MED CRI when compared 
with higher doses. 
Arterial and venous values of pH, pCO2, HCO3-, glucose, and lactate remained at 
clinically acceptable range during each dose of MED CRI, and were consistent with 
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previous findings (Pascoe et al., 2006; Lin et al. 2008). Venous values of pH, pCO2, HCO3-
, glucose, and lactate showed comparable results to arterial values with normal arterio-
venous differences and thus only arterial values were reported here. However, plasma 
glucose level is expected to increase with MED administration due to its insulin release 
inhibiting effect on pancreas that increases blood glucose levels (Short, 1992). This was not 
demonstrated in our study, probably because samples were not taken after the end of 
infusion. Medetomidine has been found to produce slow (peak in 2-4 hours post-
administration) and non-significant change in plasma glucose concentrations (Burton et al., 
1997; Ambrisko and Hikasa, 2002). Arterial lactate concentrations remained within normal 
physiologic range (below 2.5 mmol·L-1) with all dose regimens. This was consistent with 
findings from recent reports (Pascoe et al. 2006; Uilenreef et al. 2008) with DMED during 
anesthesia, implying that the overall tissue perfusion was maintained during this study. 
Again, in our study lactate measurements did not continue after MED CRI, and thus a 
potential of lactate retention during CRI may have occurred. Based on a previous study, 
some lactate retention may occur when increasing the dose of DMED CRI to 3 μg kg-1 h-1 
(Uilenreef et al., 2006) but it was not demonstrated with lower doses. Thus, it may be 
speculated that lactate retention should not occur with low dose MED CRI either. 
 
 
Conclusion 
 
With regards to the multitude of possible clinical uses of low dose DMED CRI in human 
patients (Aantaa and Jalonen, 2006; Tobias, 2007) with increasing amount of promising 
studies being published, the full advantage of these drugs may potentially follow in 
veterinary use. Such indications of MED or DMED CRI in veterinary patients could 
include the use as an adjunct to balanced anesthesia and enhance perioperative 
hemodynamic stability, as an adjunct to perioperative multimodal analgesia, and as a 
sedative-analgesic for intensive care use. 
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In conclusion, these results demonstrated the dose-dependency of the hemodynamic 
responses of MED CRI, when used as an anesthetic adjunct to ISO anesthesia in dogs. The 
low doses MED CRI (0.2-1.7 μg kg-1 h-1) induced limited and transient hemodynamic 
changes correlated to pharmacokinetics, promising enhanced hemodynamic stability, and 
showed fewer changes in pH and oxygen extraction when compared to higher doses. Thus, 
these low doses of MED CRI could be implicated to the perioperative care of canine 
patients with minimized hemodynamic changes. 
Limitations of this presented study where the low number of dogs used and the lack 
of some laboratory measurements such as insulin measurements, due to the finantial 
limitations during this study. Subsequent studies have been proceeded on the effects of 
medetomidine CRI on 24 hour echocardiogram (Appendix 1) and on the clinical efficacy 
during and after orthopaedic surgery (Appendix 2). However, further studies are warranted 
to fully demonstrate and quantify the clinical efficacy of these CRI doses as analgesic and 
anesthetic adjuncts. 
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“There are only two mistakes 
 one can make along the road to truth; 
 not going all the way, 
 and not starting.”  
Buddha 
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APPENDIX 1 
 
ABSTRACT presented in IVAPM congress in Montréal 2008. 
TITLE: Variable anti-arrhythmic effect of different dose levels of medetomidine constant 
rate infusion in isoflurane-anaesthetized dogs. 
Kaartinen J; Moreau M; Pang D; Di Fruscia R; Bélanger M-C; Gauvin D; Vainio OM; 
Cuvelliez SG; Troncy E* 
Laboratory of Inflammopharmacology – GREPAQ; Faculty of veterinary medicine – 
Université de Montréal; St-Hyacinthe (QC) Canada. 
 
   In this prospective, blinded study, 16 healthy beagles (1-3.5 years old, weighing 8.6-16.0 
kg) randomly received one of 4 medetomidine infusion regimens (4 dogs per regimen at 
1.0, 1.7, 4.0 or 12 μg/kg/h for 1h). One supplemental control group (n=3) received solely 
isoflurane. 24-hour ambulatory electrocardiography was performed. Recording was 
initiated at a minimum of 4 hours prior to induction of anaesthesia with isoflurane in 
oxygen. Prior to each infusion, a similar loading dose was given over 10 min. Each 
medetomidine dosing regimen was randomly administered twice for all dogs (protocols A 
and B). Isoflurane was administered alone for 1h before (Protocol A) or after (protocol B) a 
1h10 min administration of isoflurane combined with medetomidine CRI (2 week intervals 
between experiments). In the 12 μg/kg/h group only, the imidazoline-receptor antagonist 
efaroxan was administered intramuscularly 1h after the end of general anaesthesia. To 
control the effects of efaroxan, two additional dogs were anaesthetized with 12 μg/kg/h 
using protocol B without efaroxan administration. Electrocardiographic recordings were 
examined on hourly sessions to determine the indices of heart rate variability (HRV), heart 
rate, and cardiac conduction disturbances (ventricular premature complexes and 
atrioventricular blocks). Statistical analyses were conducted with a repeated measures 
linear model (P<0.05). 
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   Isoflurane decreased HRV indices and cardiac vagal activity (decreased RR interval and 
SDNN), an effect that was counteracted by each dose of medetomidine CRI in both A and 
B protocols. Indeed, dogs in protocol B demonstrated basal vagal activity during the one 
hour isoflurane anaesthesia after medetomidine CRI was finished. In the recovery phase, 
HRV decreased significantly in the first 3h for the 3 lower doses before increasing back to 
basal level. But in the 12 μg/kg/h group with efaroxan, HRV was normal in the initial 1h 
post-anaesthesia, and was significantly decreased for the following 5h for both protocols. 
No cardiac conduction disturbances were noted in any dog.  
   An anti-arrhythmic effect of medetomidine CRI was evident at all doses during 
anaesthesia, but was apparently present only at the highest dose tested in this study during 
the post-anaesthetic period. This potentially cardioprotective effect seems to be mediated 
by binding of medetomidine to the imidazoline receptor. 
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APPENDIX 2 
 
ABSTRACT presented in AVA/ECVAA spring congress in Helsinki 2009. 
TITLE: Comparison of clinical analgesia induced by medetomidine constant rate infusion 
and/or loco-regional anaesthesia in canine orthopaedic surgery. 
MJ Kaartinen, SG Cuvelliez, AO El-Warrak, LM Huneault, R Béraud, N Chailleux, J 
Auger, G Beauchamp, and E Troncy. Faculty of veterinary medicine – Université de 
Montréal, St-Hyacinthe & Hôpital Vétérinaire Rive-Sud, Brossard; Quebec, Canada. 
 
   This study investigated analgesic effects of a low dose medetomidine (MED) constant 
rate infusion (CRI) in dogs undergoing cranial cruciate ligament repair surgery compared to 
a loco-regional anaesthesia (LRA) technique. 
   In this prospective, blinded, controlled study, 32 client-owned dogs were randomly 
assigned to receive one of 4 treatments (n=8): 1–MED-CRI with placebo-LRA; 2–MED-
CRI with bupivacaine-LRA; 3–placebo-CRI with bupivacaine-LRA; and 4–placebo-CRI 
with placebo-LRA. Standardized anaesthesia included intramuscular pre-medication with 
butorphanol (0.3 mg·kg-1) and acepromazine (0.03 mg·kg-1), intravenous (IV) propofol 
induction, constant 1.4% end-tidal isoflurane, controlled ventilation and continuous 
multiparametric monitoring. Femoral and sciatic nerve blocks were performed using 
bupivacaine (1 mg·kg-1) or saline. Medetomidine (or saline) IV CRI was initiated before 
surgery with loading dose (0.8 mcg·kg-1) and infusion (1.7 mcg·kg-1·h-1). Post-operative 
pain was scored for 24h using the composite 4A-VET scalea. Rescue analgesia was based 
on intra-operative SAP increase and post-operative pain; and consisted of additive levels: 
hydromorphone (0.05 mg·kg-1 IV) and/or MED-CRI, and carprofen. Linear model for 
repeated measures and Cochran-Mantel-Haenszel tests were used for statistics. 
   During surgery, all dogs of Gr.4 and Gr.3 required rescue analgesia, 7/8 in Gr.1 and 5/8 in 
Gr.2. During recovery, Gr.1 showed significantly more pain than Gr.2. After surgery, Gr.3 
needed significantly lower doses of rescue analgesia compared to Gr.4 or Gr.1. None of the 
dogs with LRA needed the highest level of post-operative rescue analgesia. Neither 
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surgeon, nor surgery technique (TPLO, FLO, TTA) had a significant effect on the post-
operative pain score. 
   Neither MED-CRI, at this dosage, nor femoral/sciatic LRA were efficient analgesics in 
this study. However, their combination demonstrated a synergistic effect, both pre-
emptively (Gr.2) and after surgical pain occurrence (Gr.3 + rescue analgesia). Pre-
medication with butorphanol alone for orthopaedic surgery (Gr.4) demonstrated not only 
insufficient analgesia but also a more difficult subsequent pain management. 
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Inc. and Fonds en Santé des Animaux de Compagnie, Faculty of veterinary medicine – 
Université de Montréal. 
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